

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
22 January 2004 (22.01.2004)

PCT

(10) International Publication Number
WO 2004/006926 A1

(51) International Patent Classification⁷: **A61K 31/445**,
A61P 37/00, **C07D 413/12**, **401/12**, **211/96**, **401/14**,
495/04, **409/12**

(21) International Application Number:
PCT/GB2003/002982

(22) International Filing Date: **9 July 2003 (09.07.2003)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
0216383.0 **13 July 2002 (13.07.2002)** **GB**

(71) Applicant (for AE, AG, AL, AM, AT, AU, AZ, BA, BB, BE, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CY, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FR, GB, GD, GE, GI, GM, GR, HR, HU, ID, IE, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, SZ, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW only): **ASTRAZENECA AB [SE/SE]; Sodertalje, S-151 85 (SE)**.

(71) Applicant (for MG only): **ASTRAZENECA UK LIMITED [GB/GB]; 15 Stanhope Gate, London, Greater London W1K 1LN (GB)**.

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BURROWS, Jeremy, Nicholas [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB)**.

TUCKER, Howard [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). WATERSON, David [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). FINLAY, Maurice, Raymond, Verschoyle [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(74) Agent: **ASTRAZENECA; Global Intellectual Property, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB)**.

(81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW**.

(84) Designated States (regional): **ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)**.

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **SULPHONYLPYPERIDINE DERIVATIVES CONTAINING AN ARYL OR HETEROARYL GROUP FOR USE AS MATRIX METALLOPROTEINASE INHIBITORS**

(57) Abstract: A compound of formula (1), wherein B is an ortho substituted monocyclic aryl or heteroaryl group or a bicyclic aryl or heteroaryl group; useful in the inhibition of one or more metalloproteinases, and in particular TACE.

-1-

SULPHONYLPYPERIDINE DERIVATIVES CONTAINING AN ARYL OR HETEROARYL GROUP FOR
USE AS MATRIX METALLOPROTEINASE INHIBITORS

The present invention relates to compounds useful in the inhibition of metalloproteinases and in particular to pharmaceutical compositions comprising them, as well
5 as their use.

The compounds of this invention are inhibitors of one or more metalloproteinase enzymes and are particularly effective as inhibitors of TACE (TNF α Converting Enzyme). Metalloproteinases are a superfamily of proteinases (enzymes) whose numbers in recent years have increased dramatically. Based on structural and functional considerations these enzymes
10 have been classified into families and subfamilies as described in N.M. Hooper (1994) FEBS Letters 354:1-6. Examples of metalloproteinases include the matrix metalloproteinases (MMP) such as the collagenases (MMP1, MMP8, MMP13), the gelatinases (MMP2, MMP9), the stromelysins (MMP3, MMP10, MMP11), matrilysin (MMP7), metalloelastase (MMP12), enamelysin (MMP19), the MT-MMPs (MMP14, MMP15, MMP16, MMP17); the reprolysin
15 or adamalysin or MDC family which includes the secretases and sheddases such as TNF converting enzymes (ADAM10 and TACE); the astacin family which include enzymes such as procollagen processing proteinase (PCP); and other metalloproteinases such as aggrecanase, the endothelin converting enzyme family and the angiotensin converting enzyme family.

20 Metalloproteinases are believed to be important in a plethora of physiological disease processes that involve tissue remodelling such as embryonic development, bone formation and uterine remodelling during menstruation. This is based on the ability of the metalloproteinases to cleave a broad range of matrix substrates such as collagen, proteoglycan and fibronectin. Metalloproteinases are also believed to be important in the processing, or secretion, of
25 biologically important cell mediators, such as tumour necrosis factor (TNF); and the post translational proteolysis processing, or shedding, of biologically important membrane proteins, such as the low affinity IgE receptor CD23 (for a more complete list see N. M. Hooper *et al.*, (1997) Biochem J. 321:265-279).

Metalloproteinases have been associated with many disease conditions. Inhibition of
30 the activity of one or more metalloproteinases may well be of benefit in these disease conditions, for example: various inflammatory and allergic diseases such as, inflammation of the joint (especially rheumatoid arthritis, osteoarthritis and gout), inflammation of the gastro-

intestinal tract (especially inflammatory bowel disease, ulcerative colitis and gastritis), inflammation of the skin (especially psoriasis, eczema and dermatitis); in tumour metastasis or invasion; in disease associated with uncontrolled degradation of the extracellular matrix such as osteoarthritis; in bone resorptive disease (such as osteoporosis and Paget's disease)); in
5 diseases associated with aberrant angiogenesis; the enhanced collagen remodelling associated with diabetes, periodontal disease (such as gingivitis), corneal ulceration, ulceration of the skin, post-operative conditions (such as colonic anastomosis) and dermal wound healing; demyelinating diseases of the central and peripheral nervous systems (such as multiple sclerosis); Alzheimer's disease; and extracellular matrix remodelling observed in
10 cardiovascular diseases such as restenosis and atherosclerosis.

A number of metalloproteinase inhibitors are known; different classes of compounds may have different degrees of potency and selectivity for inhibiting various metalloproteinases. We have discovered a class of compounds that are inhibitors of metalloproteinases and are of particular interest in inhibiting TACE. The compounds of this
15 invention have beneficial potency and/or pharmacokinetic properties.

TACE (also known as ADAM17) which has been isolated and cloned [R.A. Black *et al.* (1997) *Nature* 385:729-733; M.L. Moss *et al.* (1997) *Nature* 385:733-736] is a member of the adamalysin family of metalloproteins. TACE has been shown to be responsible for the cleavage of pro-TNF α , a 26kDa membrane bound protein to release 17kDa biologically active
20 soluble TNF α . [Schlondorff *et al.* (2000) *Biochem. J.* 347: 131-138]. TACE mRNA is found in most tissues, however TNF α is produced primarily by activated monocytes, macrophages and T lymphocytes. TNF α has been implicated in a wide range of pro-inflammatory biological processes including induction of adhesion molecules and chemokines to promote cell trafficking, induction of matrix destroying enzymes, activation of fibroblasts to produce
25 prostaglandins and activation of the immune system [Aggarwal *et al* (1996) *Eur. Cytokine Netw.* 7: 93-124]. Clinical use of the anti-TNF biologicals has shown TNF α to play an important role in a range of inflammatory diseases including rheumatoid arthritis, Crohn's disease and psoriasis [Onrust *et al* (1998) *Biodrugs* 10: 397-422, Jarvis *et al* (1999) *Drugs* 57:945-964]. TACE activity has also been implicated in the shedding of other membrane
30 bound proteins including TGF α , p75 & p55 TNF receptors, L-selectin and amyloid precursor protein [Black (2002) *Int. J. Biochem. Cell Biol.* 34: 1-5]. The biology of TACE inhibition has recently been reviewed and shows TACE to have a central role in TNF α production and

selective TACE inhibitors to have equal, and possibly greater, efficacy in the collagen induced arthritis model of RA than strategies that directly neutralise TNF α [Newton et al (2001) Ann. Rheum. Dis. 60: iii25-iii32].


A TACE inhibitor might therefore be expected to show efficacy in all disease where TNF α has been implicated including, but not limited to, inflammatory diseases including rheumatoid arthritis and psoriasis, autoimmune diseases, allergic/atopic diseases, transplant rejection, graft versus host disease, cardiovascular disease, reperfusion injury and malignancy.

Compounds that inhibit matrix metalloproteinases are already known in the art. WO 00/12477 discloses hydroxamic acids and carboxylic acid derivatives that are inhibitors of matrix metalloproteinases; WO 00/12478 discloses arylpiperazines that are useful in the inhibition of matrix metalloproteinases and are of particular interest as regards the inhibition of MMP13 and MMP9; and WO 01/87870 discloses hydroxamic acid derivatives which are inhibitors of matrix metalloproteinases including ADAM or ADAM-TS enzymes.

Surprisingly we have discovered that a selection of compounds are very potent inhibitors of TACE (ADAM17) and are particularly noteworthy for their unexpected selectivity for TACE over the matrix metalloproteinases

Additionally further effective compounds are disclosed.

According to one aspect of the present invention there is provided a compound of formula (1):



formula (1)

wherein Z is selected from -CONR¹⁵OH and -N(OH)CHO;

R¹⁵ is hydrogen or C₁₋₃alkyl;

wherein R¹ is hydrogen or a group selected from C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₇cycloalkyl, C₅₋₇cycloalkenyl, aryl, heteroaryl and heterocyclyl where the group is optionally substituted by one or more substituents independently selected from halo, nitro, cyano,

trifluoromethyl, trifluoromethoxy, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, C₃₋₆cycloalkyl (optionally substituted by one or more R¹⁷), aryl (optionally substituted by one or more R¹⁷), heteroaryl (optionally substituted by one or more R¹⁷), heterocyclyl, C₁₋₄alkoxycarbonyl, -OR⁵, -SR², -SOR², -SO₂R², -COR², -CO₂R⁵, -CONR⁵R⁶, -NR¹⁶COR⁵, -SO₂NR⁵R⁶ and -NR¹⁶SO₂R²;

R¹⁶ is hydrogen or C₁₋₃alkyl;

R¹⁷ is selected from halo, C₁₋₆alkyl, C₃₋₆cycloalkyl and C₁₋₆alkoxy;

R² is group selected from C₁₋₆alkyl, C₃₋₆cycloalkyl, C₅₋₇cycloalkenyl, heterocycloalkyl, aryl, heteroaryl, arylC₁₋₄alkyl and heteroarylC₁₋₄alkyl where the group is optionally substituted by one or more halo;

R⁵ is hydrogen or a group selected from C₁₋₆alkyl, C₃₋₆cycloalkyl, C₅₋₇cycloalkenyl, heterocycloalkyl, aryl, heteroaryl, arylC₁₋₄alkyl and heteroarylC₁₋₄alkyl where the group is optionally substituted by one or more halo;

R⁶ is hydrogen, C₁₋₆alkyl or C₃₋₆cycloalkyl;

or R⁵ and R⁶ together with the nitrogen to which they are attached form a heterocyclic 4- to 7-membered ring;

wherein R⁸ is hydrogen or a group selected from C₁₋₆alkyl, C₃₋₇cycloalkyl, C₅₋₇cycloalkenyl and heterocyclyl where the group is optionally substituted by one or more substituents independently selected from halo, nitro, cyano, trifluoromethyl, trifluoromethoxy and C₁₋

alkyl;

or R¹ and R⁸ together form a carbocyclic or saturated heterocyclic 3- to 6-membered ring;

wherein R³ and R⁴ are independently hydrogen, C₁₋₆alkyl, C₃₋₆cycloalkyl, C₅₋₇cycloalkenyl, heterocyclyl, aryl or heteroaryl;

wherein n is 0 or 1;

wherein m is 0 or 1;

wherein D is hydrogen, C₁₋₄alkyl, C₃₋₆cycloalkyl or fluoro;

wherein X is O, S, SO or SO₂;

wherein B is monocyclic aryl or heteroaryl where each is substituted in an ortho position and is optionally further substituted by one or more groups independently selected from nitro,

trifluoromethyl, trifluoromethoxy, halo, C₁₋₄alkyl (optionally substituted by R¹³), C₂₋₄alkenyl (optionally substituted by R¹³), C₂₋₄alkynyl (optionally substituted by R¹³), C₃₋₆cycloalkyl (optionally substituted by R¹³), C₃₋₆cycloalkenyl (optionally substituted by R¹³), phenyl

-5-

- (optionally substituted by halo or C₁₋₄alkyl), heteroaryl (optionally substituted by halo or C₁₋₄alkyl), heterocyclyl (optionally substituted by halo or C₁₋₄alkyl), C₁₋₄alkylthio, C₃₋₆cycloalkylthio, -SOR¹³, -SO₂R¹³, -SO₂NHR¹³, -SO₂NR¹³R¹⁴, -NHSO₂R¹³, -NR¹³SO₂R¹⁴, -NHCONHR¹³, -NHCONHR¹³R¹⁴, -OR¹³, cyano, -NR¹³R¹⁴, -CONR¹³R¹⁴ and -NHCOR¹³;
- 5 or B is bicyclic aryl or heteroaryl where each is optionally substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo, C₁₋₄alkyl (optionally substituted by R¹³), C₂₋₄alkenyl (optionally substituted by R¹³), C₂₋₄alkynyl (optionally substituted by R¹³), C₃₋₆cycloalkyl (optionally substituted by R¹³), C₃₋₆cycloalkenyl (optionally substituted by R¹³), phenyl (optionally substituted by halo or C₁₋₄alkyl), heteroaryl
- 10 (optionally substituted by halo or C₁₋₄alkyl), heterocyclyl (optionally substituted by halo or C₁₋₄alkyl), C₁₋₄alkylthio, C₃₋₆cycloalkylthio, -SOR¹³, -SO₂R¹³, -SO₂NHR¹³, -SO₂NR¹³R¹⁴, -NHSO₂R¹³, -NR¹³SO₂R¹⁴, -NHCONHR¹³, -NHCONHR¹³R¹⁴, -OR¹³, cyano, -NR¹³R¹⁴, -CONR¹³R¹⁴ and -NHCOR¹³;
- R¹³ and R¹⁴ are independently hydrogen, C₁₋₆alkyl or C₃₋₆cycloalkyl;
- 15 or R¹³ and R¹⁴ together with the nitrogen to which they are attached form a heterocyclic 4 to 7-membered ring.

In a preferred embodiment of the invention:

Z is selected from -CONR¹⁵OH and -N(OH)CHO;

- 20 R¹⁵ is hydrogen or C₁₋₃alkyl;

- R¹ is hydrogen or a group selected from C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₇cycloalkyl, C₅₋₇cycloalkenyl, aryl and heteroaryl where the group is optionally substituted by one or more substituents independently selected from halo, nitro, cyano, trifluoromethyl, trifluoromethoxy, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, C₃₋₆cycloalkyl (optionally substituted by one or more R¹⁷),
- 25 aryl (optionally substituted by one or more R¹⁷), heteroaryl (optionally substituted by one or more R¹⁷), heterocyclyl, C₁₋₄alkoxycarbonyl, -OR⁵, -SR², -SOR², -SO₂R², -COR², -CO₂R⁵, -CONR⁵R⁶, -NR¹⁶COR⁵, -SO₂NR⁵R⁶ and -NR¹⁶SO₂R²;

R¹⁶ is hydrogen or C₁₋₃alkyl;

R¹⁷ is selected from halo, C₁₋₆alkyl, C₃₋₆cycloalkyl and C₁₋₆alkoxy;

- 30 R² is group selected from C₁₋₆alkyl, C₃₋₆cycloalkyl, C₅₋₇cycloalkenyl, heterocycloalkyl, aryl, heteroaryl, arylC₁₋₄alkyl and heteroarylC₁₋₄alkyl where the group is optionally substituted by one or more halo;

-6-

- R^5 is hydrogen or a group selected from C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{5-7} cycloalkenyl, heterocycloalkyl, aryl, heteroaryl, aryl C_{1-4} alkyl and heteroaryl C_{1-4} alkyl where the group is optionally substituted by one or more halo;
- R^6 is hydrogen, C_{1-6} alkyl or C_{3-6} cycloalkyl;
- 5 or R^5 and R^6 together with the nitrogen to which they are attached form a heterocyclic 4- to 7-membered ring;
- R^8 is hydrogen or a group selected from C_{1-6} alkyl, C_{3-7} cycloalkyl and C_{5-7} cycloalkenyl where the group is optionally substituted by one or more substituents independently selected from halo, nitro, cyano, trifluoromethyl, trifluoromethoxy and C_{1-4} alkyl;
- 10 R^3 and R^4 are both hydrogen;
- n is 0 or 1;
- m is 0 or 1;
- D is hydrogen, C_{1-4} alkyl, C_{3-6} cycloalkyl or fluoro;
- X is O, S, SO or SO_2 ;
- 15 B is monocyclic aryl or heteroaryl where each is substituted in an ortho position by, and is optionally further substituted by, one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo, C_{1-4} alkyl (optionally substituted by R^{13}), C_{2-4} alkenyl (optionally substituted by R^{13}), C_{2-4} alkynyl (optionally substituted by R^{13}), C_{3-6} cycloalkyl (optionally substituted by R^{13}), C_{3-6} cycloalkenyl (optionally substituted by R^{13}), phenyl
- 20 (optionally substituted by halo or C_{1-4} alkyl), heteroaryl (optionally substituted by halo or C_{1-4} alkyl), heterocyclyl (optionally substituted by halo or C_{1-4} alkyl), C_{1-4} alkylthio, C_{3-6} cycloalkylthio, $-SOR^{13}$, $-SO_2R^{13}$, $-SO_2NHR^{13}$, $-SO_2NR^{13}R^{14}$, $-NHSO_2R^{13}$, $-NR^{13}SO_2R^{14}$, $-NHCONHR^{13}$, $-NHCONHR^{13}R^{14}$, $-OR^{13}$, cyano, $-CONR^{13}R^{14}$, $-NHCOR^{13}$, $-CO^2R^{13}$ and $-CH_2CO_2R^{13}$;
- 25 or B is bicyclic aryl or heteroaryl where each is optionally substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo, C_{1-4} alkyl (optionally substituted by R^{13}), C_{2-4} alkenyl (optionally substituted by R^{13}), C_{2-4} alkynyl (optionally substituted by R^{13}), C_{3-6} cycloalkyl (optionally substituted by R^{13}), C_{3-6} cycloalkenyl (optionally substituted by R^{13}), C_{1-4} alkylthio, C_{3-6} cycloalkylthio, $-SOR^{13}$, $-SO_2R^{13}$, $-SO_2NHR^{13}$, $-SO_2NR^{13}R^{14}$, $-NHSO_2R^{13}$, $-NR^{13}SO_2R^{14}$, $-NHCONHR^{13}$, $-NHCONHR^{13}R^{14}$, $-OR^{13}$, cyano, $-CONR^{13}R^{14}$ and $-NHCOR^{13}$;
- 30 R^{13} and R^{14} are independently hydrogen, C_{1-6} alkyl or C_{3-6} cycloalkyl;

-7-

or R¹³ and R¹⁴ together with the nitrogen to which they are attached form a heterocyclic 4 to 7-membered ring.

Another aspect of the invention relates to compounds of formula (1) as hereinabove
5 defined or to a pharmaceutically acceptable salt thereof.

It is to be understood that, insofar as certain of the compounds of formula (1) defined above may exist in optically active or racemic forms by virtue of one or more asymmetric carbon or sulphur atoms, the invention includes in its definition any such optically active or racemic form which possesses metalloproteinases inhibition activity and in particular TACE
10 inhibition activity. The synthesis of optically active forms may be carried out by standard techniques of organic chemistry well known in the art, for example by synthesis from optically active starting materials or by resolution of a racemic form. Similarly, the above-mentioned activity may be evaluated using the standard laboratory techniques referred to hereinafter.

Compounds of formula (1) are therefore provided as enantiomers, diastereomers,
15 geometric isomers and atropisomers.

Within the present invention it is to be understood that a compound of formula (1) or a salt thereof may exhibit the phenomenon of tautomerism and that the formulae drawings within this specification can represent only one of the possible tautomeric forms. It is to be understood that the invention encompasses any tautomeric form which has metalloproteinases
20 inhibition activity and in particular TACE inhibition activity and is not to be limited merely to any one tautomeric form utilised within the formulae drawings. The formulae drawings within this specification can represent only one of the possible tautomeric forms and it is to be understood that the specification encompasses all possible tautomeric forms of the compounds drawn not just those forms which it has been possible to show graphically herein.

25 It is also to be understood that certain compounds of formula (1) and salts thereof can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms which have metalloproteinases inhibition activity and in particular TACE inhibition activity.

It is also to be understood that certain compounds of formula (1) may exhibit
30 polymorphism, and that the invention encompasses all such forms which possess metalloproteinases inhibition activity and in particular TACE inhibition activity.

The present invention relates to the compounds of formula (1) as hereinbefore defined as well as to the salts thereof. Salts for use in pharmaceutical compositions will be pharmaceutically acceptable salts, but other salts may be useful in the production of the compounds of formula (1) and their pharmaceutically acceptable salts. Pharmaceutically acceptable salts of the invention may, for example, include acid addition salts of the compounds of formula (1) as hereinbefore defined which are sufficiently basic to form such salts. Such acid addition salts include but are not limited to hydrochloride, hydrobromide, citrate and maleate salts and salts formed with phosphoric and sulphuric acid. In addition where the compounds of formula (1) are sufficiently acidic, salts are base salts and examples include but are not limited to, an alkali metal salt for example sodium or potassium, an alkaline earth metal salt for example calcium or magnesium, or organic amine salt for example triethylamine or tris-(2-hydroxyethyl)amine.

The compounds of formula (1) may also be provided as *in vivo* hydrolysable esters. An *in vivo* hydrolysable ester of a compound of formula (1) containing carboxy or hydroxy group is, for example a pharmaceutically acceptable ester which is cleaved in the human or animal body to produce the parent acid or alcohol. Such esters can be identified by administering, for example, intravenously to a test animal, the compound under test and subsequently examining the test animal's body fluid.

Suitable pharmaceutically acceptable esters for carboxy include C₁₋₆alkoxymethyl esters for example methoxymethyl, C₁₋₆alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters, C₃₋₈cycloalkoxycarbonyloxyC₁₋₆alkyl esters for example 1-cyclohexylcarbonyloxyethyl; 1,3-dioxolen-2-onylmethyl esters for example 5-methyl-1,3-dioxolen-2-onylmethyl; and C₁₋₆alkoxycarbonyloxyethyl esters for example 1-methoxycarbonyloxyethyl and may be formed at any carboxy group in the compounds of this invention.

Suitable pharmaceutically-acceptable esters for hydroxy include inorganic esters such as phosphate esters (including phosphoramidic cyclic esters) and α -acyloxyalkyl ethers and related compounds which as a result of the *in vivo* hydrolysis of the ester breakdown to give the parent hydroxy group/s. Examples of α -acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxymethoxy. A selection of *in vivo* hydrolysable ester forming groups for hydroxy include C₁₋₁₀alkanoyl, for example formyl, acetyl; benzoyl; phenylacetyl; substituted benzoyl and phenylacetyl; C₁₋₁₀alkoxycarbonyl (to give alkyl carbonate esters), for

example ethoxycarbonyl; di-(C₁₋₄)alkylcarbonyl and *N*-(di-(C₁₋₄)alkylaminoethyl)-*N*-(C₁₋₄)alkylcarbonyl (to give carbamates); di-(C₁₋₄)alkylaminoacetyl and carboxyacetyl. Examples of ring substituents on phenylacetyl and benzoyl include aminomethyl, (C₁₋₄)alkylaminomethyl and di-((C₁₋₄)alkyl)aminomethyl, and morpholino or piperazino linked from a ring nitrogen atom via a methylene linking group to the 3- or 4- position of the benzoyl ring. Other interesting *in vivo* hydrolysable esters include, for example, R^AC(O)O(C₁₋₆)alkyl-CO-, wherein R^A is for example, benzyloxy-(C₁₋₄)alkyl, or phenyl). Suitable substituents on a phenyl group in such esters include, for example, 4-(C₁₋₄)piperazino-(C₁₋₄)alkyl, piperazino-(C₁₋₄)alkyl and morpholino-(C₁₋₄)alkyl.

10 In this specification the generic term "alkyl" includes both straight-chain and branched-chain alkyl groups. However references to individual alkyl groups such as "propyl" are specific for the straight chain version only and references to individual branched-chain alkyl groups such as *tert*-butyl are specific for the branched chain version only. For example, "C₁₋₃alkyl" includes methyl, ethyl, propyl and isopropyl, examples of "C₁₋₄alkyl" include the 15 examples of "C₁₋₃alkyl", butyl and *tert*-butyl and examples of "C₁₋₆alkyl" include the examples of "C₁₋₄alkyl" and additionally pentyl, 2,3-dimethylpropyl, 3-methylbutyl and hexyl. Examples of "C₁₋₂₀alkyl" include the examples of "C₁₋₆alkyl" and other straight-chain and branched chain alkyl groups. An analogous convention applies to other generic terms, for example "C₂₋₄alkenyl" includes vinyl, allyl and 1-propenyl and examples of "C₂₋₆alkenyl" 20 include the examples of "C₂₋₄alkenyl" and additionally 1-butenyl, 2-butenyl, 3-butenyl, 2-methylbut-2-enyl, 3-methylbut-1-enyl, 1-pentenyl, 3-pentenyl and 4-hexenyl. Examples of "C₂₋₄alkynyl" includes ethynyl, 1-propynyl and 2-propynyl and examples of "C₂₋₆alkynyl" include the examples of "C₂₋₄alkynyl" and additionally 3-butyne, 2-pentyne and 1-methylpent-2-ynyl.

25 The term "C₃₋₆cycloalkyl" includes cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. The term "C₃₋₇cycloalkyl" includes "C₃₋₆cycloalkyl" and additionally cycloheptyl. The term "C₃₋₁₀cycloalkyl" includes "C₃₋₇cycloalkyl" and additionally cyclooctyl, cyclononyl and cyclodecyl.

"Heterocycloalkyl" is a monocyclic saturated 3- to 10-membered ring containing 1 or 30 2 heteroatoms selected from nitrogen, sulphur and oxygen wherein a ring nitrogen or sulphur may be oxidised to the N-oxide or S-oxide(s).

"C₅₋₇cycloalkenyl" is a monocyclic 5 to 7-membered ring containing 1, 2 or 3 double bonds. Examples are cyclopentenyl and cyclohexenyl.

The term "halo" refers to fluoro, chloro, bromo and iodo.

Examples of "C₁₋₄alkoxy" include methoxy, ethoxy, propoxy and isopropoxy.

5 Examples of "C₁₋₆alkoxy" include the examples of "C₁₋₄alkoxy" and additionally pentyloxy, 1-ethylpropoxy and hexyloxy. Examples of "C₁₋₄alkoxycarbonyl" include methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl and isopropoxycarbonyl. Examples of "C₁₋₄alkylthio" include methylthio, ethylthio and propylthio. Examples of "C₃₋₆cycloalkylthio" include cyclopropylthio, cyclobutylthio and cyclopentylthio. Examples of "N-C₁₋₄alkylcarbamoyl" include methylcarbamoyl, ethylcarbamoyl, propylcarbamoyl, isopropylcarbamoyl and butylcarbamoyl. Examples of "N,N-(C₁₋₄alkyl)₂carbamoyl" include dimethylcarbamoyl, methyl(ethyl)carbamoyl and diethylcabamoyl.

Examples of "aryl" are phenyl and naphthyl. An example of "monocyclic aryl" is phenyl and an example of "bicyclic aryl" is naphthyl.

15 Examples of "arylC₁₋₄alkyl" are benzyl, phenylethyl, naphthylmethyl and naphthylethyl.

"Heteroaryl" is a monocyclic or bicyclic aryl ring containing 5 to 10 ring atoms of which 1, 2, 3 or 4 ring atoms are chosen from nitrogen, sulphur or oxygen where a ring nitrogen may be oxidised. Examples of heteroaryl are pyridyl, imidazolyl, quinolinyl, cinnolyl, pyrimidinyl, thienyl, pyrrolyl, pyrazolyl, thiazolyl, oxazolyl, isoxazolyl and pyrazinyl. Preferably heteroaryl is pyridyl, imidazolyl, quinolinyl, pyrimidinyl, thienyl, pyrazolyl, thiazolyl, oxazolyl and isoxazolyl. More preferably heteroaryl is pyridyl, pyrimidinyl, thienyl, quinolinyl, thieno[2,3-*d*]pyrimidinyl and thieno[3,2-*d*]pyrimidinyl. Examples of "monocyclic heteroaryl" are pyridyl, imidazolyl, pyrimidinyl, thienyl, pyrrolyl, 20 pyrazolyl, thiazolyl, oxazolyl, isoxazolyl and pyrazinyl. Examples of "bicyclic heteroaryl" are quinolinyl, cinnolyl, thieno[2,3-*d*]pyrimidinyl, thieno[3,2-*d*]pyrimidinyl and thieno[3,2-*b*]pyridyl.

Examples of "heteroarylC₁₋₄alkyl" are pyridylmethyl, pyridylethyl, pyrimidinylethyl, pyrimidinylpropyl, quinolinylpropyl and oxazolylmethyl.

30 "Heterocyclyl" is a saturated, partially saturated or unsaturated, monocyclic or bicyclic ring containing 4 to 12 atoms of which 1, 2, 3 or 4 ring atoms are chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen

linked, wherein a -CH₂- group can optionally be replaced by a -C(O)-, a ring nitrogen or sulphur atom may be optionally oxidised to form the N-oxide or S-oxide(s) and a -NH group may be optionally substituted by acetyl, formyl, methyl or mesyl. Examples and suitable values of the term "heterocyclyl" are piperidinyl, *N*-acetylpiperidinyl, *N*-methylpiperidinyl, 5 piperazinyl, *N*-mesylpiperazinyl, *N*-formylpiperazinyl, homopiperazinyl, azetidiny, oxetanyl, morpholinyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, indolinyl, pyranyl, dihydro-2*H*-pyranyl, tetrahydrofuran-2-yl, 2,2-dimethyl-1,3-dioxolanyl and 3,4-dimethylenedioxybenzyl. Preferred values are 3,4-dihydro-2*H*-pyran-5-yl, tetrahydrofuran-2-yl, 2,2-dimethyl-1,3-dioxolan-2-yl and 3,4-dimethylenedioxybenzyl.

10 Heterocyclic rings are rings containing 1, 2 or 3 rings atoms selected nitrogen, oxygen and sulphur. "Heterocyclic 5 to 7-membered" rings are pyrrolidinyl, piperidinyl, piperazinyl, homopiperidinyl, homopiperazinyl, thiomorpholinyl, thiopyranyl and morpholinyl. "Heterocyclic 4 to 7-membered" rings include the examples of "heterocyclic 5 to 7-membered" and additionally azetidiny.

15 "Saturated heterocyclic 3 to 6-membered" rings are oxiranyl, aziridinyl, thiirane, azetidiny, oxetanyl, thietanyl, tetrahydrothienyl, pyrrolidinyl, tetrahydrofuran-2-yl, tetrahydro-2*H*-pyranyl, tetrahydro-2*H*-thiopyranyl and piperidinyl and a ring nitrogen may be substituted by a group selected from formyl, acetyl and mesyl.

A "carbocyclic 3 to 6-membered" ring is a saturated, partially saturated or unsaturated 20 ring containing 3 to 6 ring carbon atoms. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclopent-3-enyl, cyclohexyl and cyclopent-2-enyl.

Where optional substituents are chosen from "one of more" groups or substituents it is to be understood that this definition includes all substituents being chosen from one of the specified groups or the substituents being chosen from two or more of the specified groups. 25 Preferably "one or more" means "1, 2 or 3" and this is particularly the case when the group or substituent is halo. "One or more" may also means "1 or 2".

Where monocyclic aryl or heteroaryl is substituted in "an ortho position" it is to be understood that the substituent is bonded to a ring atom which is immediately adjacent to the radical ring atom (wherein the radical ring atom is the ring atom bonded to X). For example 30 an ortho substituent on pyrrol-2-yl would be located at position 1 (on the ring nitrogen) or position 3 (on a ring carbon). Similarly for pyrid-3-yl, an ortho substituent would be located at position 2 or position 4 (on a ring carbon) and for pyrid-2-yl, an ortho substituent would be

-12-

located at position 3 (on a ring carbon). For phenyl an ortho substituent would be located at position 2 or position 6.

Compounds of the present invention have been occasionally been named with the aid of computer software (ACD/Name version 5.09).

5

Preferred values of Z, R¹, R³, R⁴, R⁸, n, m, D, X and B are as follows. Such values may be used where appropriate with any of the definitions, claims or embodiments defined hereinbefore or hereinafter.

In one aspect of the present invention there is provided a compound of formula (1) as depicted above wherein Z is -CONR¹⁵OH. In another aspect of the invention Z is -N(OH)CHO.

In one aspect of the invention R¹⁵ is hydrogen, methyl, ethyl or isopropyl. In another aspect R¹⁵ is hydrogen. In a further aspect R¹⁵ is methyl, ethyl or isopropyl.

In one aspect of the invention R¹ is hydrogen or a group selected from C₁₋₆alkyl, C₂₋₆alkynyl, C₃₋₇cycloalkyl, aryl and heteroaryl where the group is optionally substituted by one or more substituents independently selected from halo, nitro, cyano, trifluoromethyl, C₁₋₄alkyl, C₃₋₆cycloalkyl, aryl (optionally substituted by R¹⁷), heteroaryl (optionally substituted by R¹⁷), C₁₋₄alkoxycarbonyl, -OR⁵, -SR², -SOR², -SO₂R², -COR², -CO₂R⁵ and -NR¹⁶COR⁵. In another aspect R¹ is a group selected from C₁₋₆alkyl, aryl and heteroaryl each being optionally substituted by one or more substituents independently selected from C₁₋₄alkyl, C₃₋₆cycloalkyl (optionally substituted by R¹⁷), aryl (optionally substituted by R¹⁷) and heteroaryl (optionally substituted by R¹⁷). In another aspect R¹ is a group selected from C₁₋₆alkyl, C₃₋₆cycloalkyl, aryl, heteroaryl and C₁₋₆alkyl substituted by aryl or heteroaryl wherein any R¹ group is optionally substituted by one or more substituents independently selected from halo, C₁₋₄alkoxy, C₁₋₄alkyl and C₃₋₆cycloalkyl. In another aspect of the invention R¹ is hydrogen or a group selected from methyl, ethyl, propyl, isopropyl, *tert*-butyl, isobutyl, ethynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, pyridyl, thienyl, pyrimidinyl, quinolinyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl and imidazolyl, where the group is optionally substituted by one or more substituents independently selected from fluoro, chloro, bromo, nitro, cyano, trifluoromethyl, methyl, ethyl, C₃₋₆cycloalkyl, phenyl (optionally substituted by halo or C₁₋₄alkyl), pyrimidinyl (optionally substituted by halo or C₁₋₄alkyl), C₁₋₄alkoxycarbonyl, -OR⁵, -SR², -SOR², -SO₂R², -COR², -CO₂R⁵ and -NR¹⁶COR⁵. In a

30

-13-

further aspect of the invention R^1 is selected from hydrogen, methyl, ethyl, propyl, isopropyl, *tert*-butyl, isobutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, benzyloxymethyl, phenyl, benzyl, phenylethyl, phenylpropyl, (5-fluoropyrimidin-2-yl)ethyl, (5-fluoropyrimidin-2-yl)propyl, pyrimidin-2-ylethyl, pyrimidin-2-ylpropyl, naphth-2-yl, naphth-1-yl, 3,4-dichlorophenyl, 4-chlorophenyl, biphenyl, 3-nitrophenyl, 2-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 3-bromophenyl, 4-(methoxycarbonyl)phenyl, 4-benzyloxyphenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 3-(4-chlorophenoxy)phenyl, 2-cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, 2-bromothien-5-yl, 2-methylthien-5-yl, pyrimidin-2-yl, 2-methylpyrimidin-5-yl, 2-methylpyrimidin-4-yl, quinolin-4-yl, ethynyl, methoxymethyl, thiazol-2-yl, oxazol-2-yl, isoxazol-5-yl, 4,4-difluorocyclohexyl, pyrimidin-2-ylmethyl, 2-pyrimidin-2-ylethyl, 3-pyrimidin-2-ylpropyl, 2,2,2-trifluoroethyl, 3-bromo-4-hydroxyphenyl, 4-fluoro-2-trifluoromethylphenyl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, imidazol-4-yl, 1*H*-imidazol-4-yl, pyrazol-3-yl, 1*H*-pyrazol-3-yl and (*N*-acetyl amino)phenyl. In another aspect R^1 is propyl, cyclopentyl, phenyl or pyridyl optionally substituted by methyl, ethyl, phenyl, pyridyl or pyrimidinyl. In a further aspect R^1 is isobutyl, cyclopentyl, 3-(pyrimidin-2-yl)propyl, phenyl or pyrid-3-yl.

In one aspect of the invention R^{16} is hydrogen, methyl or ethyl. In another aspect R^{16} is methyl or ethyl. In another aspect of the invention R^{16} is hydrogen.

In one aspect of the invention R^{17} is halo or C_{1-4} alkyl. In another aspect R^{17} is fluoro, chloro, bromo or methyl. In another aspect of the invention R^{17} is fluoro or methyl.

In one aspect of the invention R^2 is a group selected from C_{1-6} alkyl, aryl and aryl C_{1-4} alkyl where the group is optionally substituted by halo. In another aspect R^2 is a group selected from methyl, phenyl and benzyl where the group is optionally substituted by chloro. In one aspect of the invention R^2 is methyl.

In one aspect of the invention R^5 is hydrogen or a group selected from C_{1-6} alkyl, aryl and aryl C_{1-4} alkyl where the group is optionally substituted by halo. In another aspect R^5 is hydrogen or a group selected from methyl, phenyl and benzyl where the group is optionally substituted by chloro.

In one aspect of the invention R^6 is hydrogen, methyl, ethyl, propyl or isopropyl.

In one aspect of the invention R^8 is hydrogen, methyl, ethyl, propyl or isopropyl. In another aspect R^8 is hydrogen.

-14-

In one aspect of the invention R^3 is hydrogen, methyl, ethyl or phenyl. In another aspect R^3 is hydrogen.

In one aspect of the invention R^4 is hydrogen, methyl, ethyl or phenyl. In another aspect R^4 is hydrogen.

5 In one aspect of the invention n is 0. In another aspect n is 1.

In one aspect of the invention m is 0. In another aspect of the invention m is 1.

In one aspect of the invention D is hydrogen, methyl or fluoro. In another aspect D is hydrogen.

In one aspect of the invention X is O.

10 In one aspect of the invention B is phenyl or pyridyl where each is substituted in an ortho position by, and is optionally further substituted by one or more groups independently selected from chloro, fluoro, bromo, trifluoromethyl, cyano, acetamido, propyloxy, methoxy, methyl, nitro, pyrrolidinylcarbonyl, *N*-propylcarbamoyl, pyrrolidinyl, piperidinyl, isoxazolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, pyrimidinyl and pyridyl; or B is naphthyl, quinoliny, 1,6-naphthyridinyl, thieno[2,3-*d*]pyrimidinyl, thieno[3,2-*d*]pyrimidinyl or thieno[3,2-*b*]pyridyl each being optionally substituted by one or more groups independently selected from chloro, fluoro, bromo, trifluoromethyl, cyano, acetamido, propyloxy, methoxy, methyl, nitro, pyrrolidinylcarbonyl *N*-propylcarbamoyl, pyrrolidinyl, piperidinyl, isoxazolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, pyrimidinyl and pyridyl. In one aspect of the invention B is phenyl or pyridyl where each is substituted in an ortho position by, and is optionally further substituted by one or more groups independently selected from chloro, fluoro, bromo, trifluoromethyl, cyano, acetamido, propyloxy, methoxy, ethoxy, isopropoxy, methyl, ethyl, propyl, isopropyl, nitro, pyrrolidinylcarbonyl, *N*-propylcarbamoyl, *N*-isopropylcarbamoyl, *N*-ethylcarbamoyl and *N*-methylcarbamoyl; or B is naphthyl, quinoliny, 1,6-naphthyridinyl, thieno[2,3-*d*]pyrimidinyl, thieno[3,2-*d*]pyrimidinyl or thieno[3,2-*b*]pyridyl each being optionally substituted by one or more groups independently selected from chloro, fluoro, bromo, trifluoromethyl, cyano, acetamido, propyloxy, methoxy, methyl, nitro, pyrrolidinylcarbonyl and *N*-propylcarbamoyl. In another aspect B is phenyl or pyridyl where each is substituted in an ortho position by, and is optionally further substituted by one or more groups independently selected from halo, trifluoromethyl, cyano, C_{1-4} alkoxy, C_{1-4} alkyl, nitro, aryl, heteroaryl, heterocyclyl, *N*-(C_{1-4} alkyl)carbamoyl and *N,N*-(C_{1-4} alkyl)₂carbamoyl; or B is naphthyl, quinoliny, thieno[2,3-*d*]pyrimidinyl or thieno[3,2-*d*]pyrimidinyl each being

15
20
25
30

optionally substituted by one or more groups independently selected from halo, trifluoromethyl, cyano, C₁₋₄alkoxy, C₁₋₄alkyl, aryl, heteroaryl, heterocyclyl and nitro. In another aspect B is phenyl or pyridyl where each is substituted in an ortho position by, and is optionally further substituted by one or more groups independently selected from halo, trifluoromethyl, cyano, C₁₋₄alkoxy, C₁₋₄alkyl, nitro, *N*-(C₁₋₄alkyl)carbamoyl and *N,N*-(C₁₋₄alkyl)₂carbamoyl; or B is naphthyl, quinolinyl, thieno[2,3-*d*]pyrimidinyl or thieno[3,2-*d*]pyrimidinyl all being optionally substituted by one or more groups independently selected from halo, trifluoromethyl, cyano, C₁₋₄alkoxy, C₁₋₄alkyl and nitro. In one aspect of the invention B is phenyl or pyridyl where each is substituted in an ortho position by, and is optionally further substituted by one or more groups independently selected from chloro, fluoro, bromo, trifluoromethyl, cyano, isopropoxy, methoxy, methyl, nitro, *N*-isopropylcarbamoyl, phenyl, pyridyl, pyrimidinyl, thienyl, isoxazolyl and piperidinyl; or B is naphthyl, thieno[2,3-*d*]pyrimidinyl or thieno[3,2-*d*]pyrimidinyl each being optionally substituted by one or more groups independently selected from chloro, fluoro, bromo, trifluoromethyl, cyano, methoxy, methyl, nitro, phenyl, pyridyl, pyrimidinyl, thienyl, isoxazolyl and piperidinyl. In one aspect of the invention B is phenyl or pyridyl where each is substituted in an ortho position by, and is optionally further substituted by one or more groups independently selected from chloro, fluoro, bromo, trifluoromethyl, cyano, isopropoxy, methoxy, methyl, nitro and *N*-isopropylcarbamoyl; or B is naphthyl, thieno[2,3-*d*]pyrimidinyl or thieno[3,2-*d*]pyrimidinyl each being optionally substituted by one or more groups independently selected from chloro, fluoro, bromo, trifluoromethyl, cyano, methoxy, methyl and nitro. In another aspect B is selected from naphthyl, 2-chloro-4-fluorophenyl, 2-chloro-4-trifluoromethylphenyl, 2-bromo-4,6-difluorophenyl, 2-bromo-4-fluorophenyl, 2,4-dichlorophenyl, 2-cyanophenyl, 2-bromophenyl, 2-chlorophenyl, 2-acetamidophenyl, 2-(isopropoxy)phenyl, 2-trifluoromethylphenyl, 2-bromo-4-chlorophenyl, 2-methoxy-4-methylphenyl, 4-chloro-2-nitrophenyl, 4-methyl-2-nitrophenyl, 2,4-difluorophenyl, 2-nitrophenyl, 4-bromo-2-fluorophenyl, 2-methoxy-4-nitrophenyl, 2-(pyrrolidin-1-ylcarbonyl)phenyl, 2-chloro-4-nitrophenyl, 2-(*N*-isopropyl)carbamoylphenyl, 2-(pyrrolidin-1-yl)phenyl, 2-(piperidin-1-yl)phenyl, 4-bromo-2-methoxyphenyl, 2-fluoro-4-nitrophenyl, 2-chloro-4-bromophenyl, 2-chloro-4-methylphenyl, 2-chloro-4-methoxyphenyl, 4-fluoro-2-methoxyphenyl, 2-fluoro-4-chlorophenyl, 4-fluoro-2-methylphenyl, 2-(isoxazol-5-yl)phenyl, 3-chloropyrid-2-yl, quinolin-4-yl, 7-chloroquinolin-4-yl, 3-cyanopyrid-2-yl, 8-chloroquinolin-

4-yl, 3-trifluoromethylpyrid-2-yl, 3-chloro-5-trifluoromethylpyrid-2-yl, 3,5-dichloropyrid-2-yl, 6-chloroquinolin-4-yl, 5-methylthieno[2,3-*d*]pyrimidin-4-yl, 7-methylthieno[3,2-*d*]pyrimidin-4-yl, 8-fluoroquinolin-4-yl, 2-pyrazol-5-ylphenyl, 4-chloro-2-(isoxazol-5-yl)phenyl, 2-(isoxazol-5-yl)-4-trifluoromethylphenyl, 2-imidazol-5-ylphenyl, 2-(oxazol-5-yl)phenyl, 2-(thiazol-5-yl)phenyl, 2-(pyrimidin-2-yl)phenyl, 2-(pyrid-2-yl)phenyl, 6-fluoroquinolin-4-yl, 2-methylquinolin-4-yl, 6-chloro-2-methylquinolin-4-yl, 1,6-naphthyridin-4-yl, thieno[3,2-*b*]pyrid-7-yl, 5-fluoro-2-(isoxazol-5-yl)phenyl, 4-fluoro-2-(isoxazol-5-yl)phenyl, 4-chloro-2-trifluoromethylphenyl and 2-chloro-5-fluorophenyl. In another aspect B is 4-fluoro-(2-thiophenyl)phenyl, 4-fluoro-2-(pyrid-2-yl)phenyl. In a further aspect B is selected from 2-chloro-4-trifluoromethylphenyl, 2-bromo-4-fluorophenyl, 2-bromophenyl, 2-chlorophenyl, 2-chloro-4-fluorophenyl, 2,4-dichlorophenyl, 2-(isopropoxy)phenyl, 2-trifluoromethylphenyl, 4-chloro-2-nitrophenyl, 4-methyl-2-nitrophenyl, 2-methoxy-4-nitrophenyl, 2-(*N*-isopropyl)carbamoylphenyl, 2-fluoro-4-nitrophenyl, 2-chloro-4-methylphenyl, 2-chloro-4-methoxyphenyl, 4-fluoro-2-methoxyphenyl, 2-fluoro-4-chlorophenyl, 4-fluoro-2-methylphenyl, 3-chloropyrid-2-yl, 3-cyanopyrid-2-yl, 8-chloroquinolin-4-yl, 3-trifluoromethylpyrid-2-yl, 3-chloro-5-trifluoromethylpyrid-2-yl, 3,5-dichloropyrid-2-yl, 5-methylthieno[2,3-*d*]pyrimidin-4-yl, 7-methylthieno[3,2-*d*]pyrimidin-4-yl, naphthyl, 2-bromo-4,6-difluorophenyl, 2-cyanophenyl, 2-isoxazol-5-ylphenyl, 2-piperidin-1-ylphenyl, 4-fluoro-2-thien-3-ylphenyl and 4-fluoro-2-pyrid-3-ylphenyl. In a further aspect B is selected from 2-chloro-4-trifluoromethylphenyl, 2-bromo-4-fluorophenyl, 2-bromophenyl, 2-chlorophenyl, 2-chloro-4-fluorophenyl, 2,4-dichlorophenyl, 2-(isopropoxy)phenyl, 2-trifluoromethylphenyl, 4-chloro-2-nitrophenyl, 4-methyl-2-nitrophenyl, 2-methoxy-4-nitrophenyl, 2-(*N*-isopropyl)carbamoylphenyl, 2-fluoro-4-nitrophenyl, 2-chloro-4-methylphenyl, 2-chloro-4-methoxyphenyl, 4-fluoro-2-methoxyphenyl, 2-fluoro-4-chlorophenyl, 4-fluoro-2-methylphenyl, 3-chloropyrid-2-yl, 3-cyanopyrid-2-yl, 8-chloroquinolin-4-yl, 3-trifluoromethylpyrid-2-yl, 3-chloro-5-trifluoromethylpyrid-2-yl, 3,5-dichloropyrid-2-yl, 5-methylthieno[2,3-*d*]pyrimidin-4-yl, 7-methylthieno[3,2-*d*]pyrimidin-4-yl, naphthyl, 2-bromo-4,6-difluorophenyl and 2-cyanophenyl.

In one aspect of the invention R¹³ is C₁₋₆alkyl. In another aspect R¹³ is methyl or isopropyl.

In one aspect of the invention R¹⁴ is hydrogen

-17-

In one aspect of the invention R^{13} and R^{14} together with the nitrogen to which they are attached form pyrrolidinyl or piperidinyl.

A preferred class of compound is of formula (1) wherein;

5 Z is $-N(OH)CHO$;

R^1 is hydrogen or a group selected from C_{1-6} alkyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, aryl and heteroaryl where the group is optionally substituted by one or more substituents independently selected from halo, nitro, cyano, trifluoromethyl, C_{1-4} alkyl, C_{3-6} cycloalkyl, aryl (optionally substituted by R^{17}), heteroaryl (optionally substituted by R^{17}), C_{1-4} alkoxycarbonyl, $-OR^5$, $-SR^2$, $-SOR^2$, $-SO_2R^2$, $-COR^2$, $-CO_2R^5$ and $-NR^{16}COR^5$;

R^{16} is hydrogen, methyl or ethyl;

R^{17} is halo or C_{1-4} alkyl;

R^2 is a group selected from C_{1-6} alkyl, aryl and aryl C_{1-4} alkyl where the group is optionally substituted by halo;

15 R^5 is hydrogen or a group selected from C_{1-6} alkyl, aryl and aryl C_{1-4} alkyl where the group is optionally substituted by halo;

R^6 is hydrogen, methyl, ethyl, propyl or isopropyl;

R^8 is hydrogen, methyl, ethyl, propyl or isopropyl;

R^3 is hydrogen;

20 R^4 is hydrogen;

n is 0;

m is 1;

D is hydrogen, methyl or fluoro;

X is O;

25 B is phenyl or pyridyl where each is substituted in an ortho position by, and is optionally further substituted by one or more groups independently selected from halo, trifluoromethyl, cyano, C_{1-4} alkoxy, C_{1-4} alkyl, nitro, aryl, heteroaryl, heterocyclyl, $N-(C_{1-4}alkyl)carbamoyl$ and $N,N-(C_{1-4}alkyl)_2carbamoyl$; or B is naphthyl, quinolinyl, thieno[2,3-*d*]pyrimidinyl or thieno[3,2-*d*]pyrimidinyl all being optionally substituted by one or more
30 groups independently selected from halo, trifluoromethyl, cyano, C_{1-4} alkoxy, C_{1-4} alkyl, aryl, heteroaryl, heterocyclyl and nitro.

-18-

Another preferred class of compound is of formula (1) wherein:

Z is $-\text{CONR}^{15}(\text{OH})$;

R^{15} is hydrogen, methyl, ethyl or isopropyl

R^1 is hydrogen or a group selected from C_{1-6} alkyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, aryl and
5 heteroaryl where the group is optionally substituted by one or more substituents independently
selected from halo, nitro, cyano, trifluoromethyl, C_{1-4} alkyl, C_{3-6} cycloalkyl, aryl (optionally
substituted by R^{17}), heteroaryl (optionally substituted by R^{17}), C_{1-4} alkoxycarbonyl, $-\text{OR}^5$, $-\text{SR}^2$, $-\text{SOR}^2$, $-\text{SO}_2\text{R}^2$, $-\text{COR}^2$, $-\text{CO}_2\text{R}^5$ and $-\text{NR}^{16}\text{COR}^5$;

R^{16} is hydrogen, methyl or ethyl;

10 R^{17} is halo or C_{1-4} alkyl;

R^2 is a group selected from C_{1-6} alkyl, aryl and aryl C_{1-4} alkyl where the group is
optionally substituted by halo;

R^5 is hydrogen or a group selected from C_{1-6} alkyl, aryl and aryl C_{1-4} alkyl where the
group is optionally substituted by halo;

15 R^3 is hydrogen;

R^4 is hydrogen;

R^8 is hydrogen;

n is 0;

m is 1;

20 D is hydrogen, methyl or fluoro;

X is O;

B is phenyl or pyridyl where each is substituted in an ortho position by, and is
optionally further substituted by one or more groups independently selected from halo,
trifluoromethyl, cyano, C_{1-4} alkoxy, C_{1-4} alkyl, nitro, aryl, heteroaryl, heterocyclyl, $N-(\text{C}_{1-4}$
25 C_{1-4} alkyl)carbamoyl and $N,N-(\text{C}_{1-4}$ alkyl) $_2$ carbamoyl; or B is naphthyl, quinolinyl, thieno[2,3-
d]pyrimidinyl or thieno[3,2-*d*]pyrimidinyl all being optionally substituted by one or more
groups independently selected from halo, trifluoromethyl, cyano, C_{1-4} alkoxy, C_{1-4} alkyl, aryl,
heteroaryl, heterocyclyl and nitro.

30 Another preferred class is of compound of formula (1) wherein:

Z is $-\text{CONHOH}$ or $-\text{N}(\text{OH})\text{CHO}$;

-19-

R^1 is a group selected from C_{1-6} alkyl, C_{3-6} cycloalkyl, aryl, heteroaryl and C_{1-6} alkyl substituted by aryl or heteroaryl wherein any R^1 group is optionally substituted by one or more substituents independently selected from halo, C_{1-4} alkoxy, C_{1-4} alkyl and C_{3-6} cycloalkyl;

R^3 is hydrogen;

5 R^4 is hydrogen;

R^8 is hydrogen;

n is 0;

m is 1;

D is hydrogen;

10 X is O; and

B is phenyl or pyridyl where each is substituted in an ortho position by, and is optionally further substituted by one or more groups independently selected from halo, trifluoromethyl, cyano, C_{1-4} alkoxy, C_{1-4} alkyl, nitro, N -(C_{1-4} alkyl)carbamoyl and N,N -(C_{1-4} alkyl)₂carbamoyl; or B is naphthyl, quinoliny, thieno[2,3-*d*]pyrimidinyl or thieno[3,2-*d*]pyrimidinyl all being optionally substituted by one or more groups independently selected
15 from halo, trifluoromethyl, cyano, C_{1-4} alkoxy, C_{1-4} alkyl and nitro.

Another preferred class is of compound of formula (1) wherein:

Z is -CONHOH or N(OH)CHO ;

20 R^1 is a group selected from C_{1-6} alkyl, C_{3-6} cycloalkyl, aryl, heteroaryl and C_{1-6} alkyl substituted by aryl or heteroaryl wherein any R^1 group is optionally substituted by one or more substituents independently selected from halo, C_{1-4} alkoxy, C_{1-4} alkyl and C_{3-6} cycloalkyl;

R^3 is hydrogen;

R^4 is hydrogen;

25 R^8 is hydrogen;

n is 0;

m is 1;

D is hydrogen;

B is phenyl or pyridyl where each is substituted in an ortho position by, and is
30 optionally further substituted by one or more groups independently selected from chloro, fluoro, bromo, trifluoromethyl, cyano, isopropoxy, methoxy, methyl, nitro, N -isopropylcarbamoyl, phenyl, pyridyl, pyrimidinyl, thienyl, isoxazolyl and piperidinyl; or B is

-20-

naphthyl, thieno[2,3-*d*]pyrimidinyl or thieno[3,2-*d*]pyrimidinyl each being optionally substituted by one or more groups independently selected from chloro, fluoro, bromo, trifluoromethyl, cyano, methoxy, methyl, nitro, phenyl, pyridyl, pyrimidinyl, thienyl, isoxazolyl and piperidinyl.

5

Another preferred class is of compound of formula (1) wherein:

Z is -CONHOH or -N(OH)CHO;

R¹ is propyl, cyclopentyl, phenyl or pyridyl optionally substituted by methyl, ethyl, phenyl, pyridyl or pyrimidinyl;

10 R³ is hydrogen;

R⁴ is hydrogen;

R⁸ is hydrogen;

n is 0;

m is 1;

15 D is hydrogen;

X is O; and

B is phenyl or pyridyl where each is substituted in an ortho position by, and is optionally further substituted by one or more groups independently selected from chloro, fluoro, bromo, trifluoromethyl, cyano, isopropoxy, methoxy, methyl, nitro and *N*-

20 isopropylcarbamoyl; or B is naphthyl, thieno[2,3-*d*]pyrimidinyl or thieno[3,2-*d*]pyrimidinyl each being optionally substituted by one or more groups independently selected from chloro, fluoro, bromo, trifluoromethyl, cyano, methoxy, methyl and nitro.

In another aspect of the invention, preferred compounds of the invention are any one
25 of:

1-([4-(1-naphthyloxy)piperidin-1-yl]sulphonyl)methyl)-4-pyrimidin-2-ylbutyl(hydroxy)formamide;

1-([4-(2-chloro-4-fluorophenoxy)piperidin-1-yl]sulphonyl)methyl)-4-pyrimidin-2-ylbutyl(hydroxy)formamide;

1-([4-(2-chloro-4-(trifluoromethyl)phenoxy)piperidin-1-yl]sulphonyl)methyl)-4-pyrimidin-2-ylbutyl(hydroxy)formamide;

1-([4-(2-bromo-4,6-difluorophenoxy)piperidin-1-yl]sulphonyl)methyl)-4-pyrimidin-2-

ylbutyl(hydroxy)formamide;

1-([4-(2-bromo-4-fluorophenoxy)piperidin-1-yl]sulphonyl)methyl)-4-pyrimidin-2-ylbutyl(hydroxy)formamide;

1-([4-(2,4-dichlorophenoxy)piperidin-1-yl]sulphonyl)methyl)-4-pyrimidin-2-ylbutyl(hydroxy)formamide;

1-([4-(2-cyanophenoxy)piperidin-1-yl]sulphonyl)methyl)-4-pyrimidin-2-ylbutyl(hydroxy)formamide;

2-([4-(2-cyanophenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide;

2-([4-(2-bromophenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide;

2-([4-(2-chlorophenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide;

2-([4-(2-chloro-4-fluorophenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide;

2-([4-(2,4-dichlorophenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide;

2-([4-(2-acetamidophenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide;

2-([4-(2-isopropoxyphenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide;

2-([4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide;

2-([4-(2-bromo-4-chlorophenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide;

2-([4-(2-methoxy-4-methylphenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide;

2-([4-(4-chloro-2-nitrophenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide;

2-([4-(4-methyl-2-nitrophenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide;

2-([4-(2,4-difluorophenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide;

2-([4-(2-bromo-4-fluorophenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide;

2-([4-(2-nitrophenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide;

2-([4-(4-bromo-2-fluorophenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide;

2-([4-(2-methoxy-4-nitrophenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide;

2-([4-[2-(pyrrolidin-1-ylcarbonyl)phenoxy]piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide;

2-([4-(2-chloro-4-nitrophenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide;

2-([4-(2-(*N*-isopropylcarbonyl)phenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide;

2-([4-(2-pyrrolidin-1-ylphenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide;

2-([4-(2-piperidin-1-ylphenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide;

2-([4-(4-bromo-2-methoxyphenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide;

2-([4-(2-fluoro-4-nitrophenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide;

2-([4-(2-chloro-4-methylphenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide;

2-([4-(2-chloro-4-methoxyphenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide;

2-([4-(4-fluoro-2-methoxyphenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide;

2-([4-(4-chloro-2-fluorophenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide;

2-([4-(4-fluoro-2-methylphenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide;

2-([4-(2-isoxazol-5-ylphenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide;

2-([4-[(3-chloropyrid-2-yl)oxy]piperidin-1-yl]sulphonyl)-1-pyrid-3-ylethyl(hydroxy)formamide;

2-([4-(quinolin-4-yloxy)piperidin-1-yl]sulphonyl)-1-pyrid-3-ylethyl(hydroxy)formamide;

-23-

2-({4-[(7-chloroquinolin-4-yl)oxy]piperidin-1-yl}sulphonyl)-1-pyrid-3-ylethyl(hydroxy)formamide;
 2-({4-[(3-cyanopyrid-2-yl)oxy]piperidin-1-yl}sulphonyl)-1-pyrid-3-ylethyl(hydroxy)formamide;
 2-({4-[(8-chloroquinolin-4-yl)oxy]piperidin-1-yl}sulphonyl)-1-pyrid-3-ylethyl(hydroxy)formamide;
 2-[(4-{[3-(trifluoromethyl)pyrid-2-yl]oxy}piperidin-1-yl)sulphonyl]-1-pyrid-3-ylethyl(hydroxy)formamide;
 2-[(4-{[3-chloro-5-(trifluoromethyl)pyrid-2-yl]oxy}piperidin-1-yl)sulphonyl]-1-pyrid-3-ylethyl(hydroxy)formamide;
 2-({4-[(3,5-dichloropyrid-2-yl)oxy]piperidin-1-yl}sulphonyl)-1-pyrid-3-ylethyl(hydroxy)formamide;
 2-({4-[(6-chloroquinolin-4-yl)oxy]piperidin-1-yl}sulphonyl)-1-pyrid-3-ylethyl(hydroxy)formamide;
 2-({4-[(5-methylthieno[2,3-*d*]pyrimidin-4-yl)oxy]piperidin-1-yl}sulphonyl)-1-pyrid-3-ylethyl(hydroxy)formamide;
 2-({4-[(7-methylthieno[3,2-*d*]pyrimidin-4-yl)oxy]piperidin-1-yl}sulphonyl)-1-pyrid-3-ylethyl(hydroxy)formamide; and
 2-({4-[(8-fluoroquinolin-4-yl)oxy]piperidin-1-yl}sulphonyl)-1-pyrid-3-ylethyl(hydroxy)formamide.

In a further aspect of the invention, preferred compounds of the invention are any one of:

- (R/S)- 1-[(4-[2-chloro-4-(trifluoromethyl)phenoxy]piperidin-1-yl)sulphonyl)methyl]-4-pyrimidin-2-ylbutyl(hydroxy)formamide;
 5 (R/S)- 1-[(4-(2-bromo-4-fluorophenoxy)piperidin-1-yl)sulphonyl)methyl]-4-pyrimidin-2-ylbutyl(hydroxy)formamide;
 (R/S)-2-[(4-(2-bromophenoxy)piperidin-1-yl)sulphonyl]-1-phenylethyl(hydroxy)formamide;
 (R/S)-2-[(4-(2-chlorophenoxy)piperidin-1-yl)sulphonyl]-1-phenylethyl(hydroxy)formamide;
 10 (R/S)-2-[(4-(2-chloro-4-fluorophenoxy)piperidin-1-yl)sulphonyl]-1-phenylethyl(hydroxy)formamide;

- (R/S)-2-([4-(2,4-dichlorophenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide;
- (R/S)-hydroxy(2-([4-(2-isopropoxyphenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl)formamide;
- 5 (R/S)-hydroxy(2-([4-(2-trifluoromethylphenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl)formamide;
- (R/S)-2-([4-(4-chloro-2-nitrophenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide;
- (R/S)-hydroxy(2-([4-(4-methyl-2-nitrophenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl)formamide;
- 10 (R/S)-2-([4-(2-bromo-4-fluorophenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide;
- (R/S)-hydroxy(2-([4-(2-methoxy-4-nitrophenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl)formamide;
- 15 (R/S)-hydroxy[2-([4-(2-(isopropylaminocarbonyl)phenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl]formamide;
- (R/S)-2-([4-(2-fluoro-4-nitrophenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide;
- (R/S)-2-([4-(2-chloro-4-methylphenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide;
- 20 (R/S)-2-([4-(2-chloro-4-methoxyphenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide;
- (R/S)-2-([4-(4-fluoro-2-methoxyphenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide;
- 25 (R/S)-2-([4-(4-chloro-2-fluorophenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide;
- (R/S)-2-([4-(4-fluoro-2-methylphenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide;
- (R/S)-2-([4-[(3-chloropyridin-2-yl)oxy]piperidin-1-yl]sulphonyl)-1-pyridin-3-ylethyl(hydroxy)formamide;
- 30 (R/S)-2-([4-[(3-cyanopyridin-2-yl)oxy]piperidin-1-yl]sulphonyl)-1-pyridin-3-ylethyl(hydroxy)formamide;

- (R/S)-2-({4-[(8-chloroquinolin-4-yl)oxy]piperidin-1-yl}sulphonyl)-1-pyridin-3-ylethyl(hydroxy)formamide;
- (R/S)-hydroxy{1-pyridin-3-yl-2-[(4-{[3-(trifluoromethyl)pyridin-2-yl]oxy}piperidin-1-yl)sulphonyl]ethyl}formamide;
- 5 (R/S)-2-[(4-{[3-chloro-5-(trifluoromethyl)pyridin-2-yl]oxy}piperidin-1-yl)sulphonyl]-1-pyridin-3-ylethyl(hydroxy)formamide;
- (R/S)-2-[(4-{[3-chloro-5-chloropyridin-2-yl]oxy}piperidin-1-yl)sulphonyl]-1-pyridin-3-ylethyl(hydroxy)formamide;
- (R/S)-hydroxy[2-({4-[(5-methylthieno[2,3-d]pyrimidin-4-yl)oxy]piperidin-1-yl}sulphonyl)-1-pyridin-3-ylethyl]formamide;
- 10 (R/S)-hydroxy[2-({4-[(7-methylthieno[3,2-d]pyrimidin-4-yl)oxy]piperidin-1-yl}sulphonyl)-1-pyridin-3-ylethyl]formamide;
- (R/S)-2-({[4-(2-bromo-4-fluorophenoxy)piperidin-1-yl]sulphonyl}methyl)-N-hydroxy-4-methylpentanamide ;
- 15 (R/S)-3-{{[4-(2-bromo-4-fluorophenoxy)piperidin-1-yl]sulphonyl}-2-cyclopentyl-N-hydroxypropanamide;
- (R/S)-1-[[({4-[1-naphthyloxy]piperidin-1-yl}sulphonyl)methyl]-4-pyrimidin-2-ylbutyl(hydroxy)formamide;
- (R/S)-1-[[({4-[2-chloro-4-fluorophenoxy]piperidin-1-yl}sulphonyl)methyl]-4-pyrimidin-2-ylbutyl(hydroxy)formamide;
- 20 (R/S)-1-[[({4-[2-bromo-4,6-difluorophenoxy]piperidin-1-yl}sulphonyl)methyl]-4-pyrimidin-2-ylbutyl(hydroxy)formamide;
- (R/S)-1-[[({4-[2,4-dichlorophenoxy]piperidin-1-yl}sulphonyl)methyl]-4-pyrimidin-2-ylbutyl(hydroxy)formamide; and
- 25 (R/S)-1-[[({4-[2-cyanophenoxy]piperidin-1-yl}sulphonyl)methyl]-4-pyrimidin-2-ylbutyl(hydroxy)formamide.


Further compounds of the invention, which may be listed with the compounds named above are any one of:

- 30 (R/S)-2-{{[4-(2-isoxazol-5-ylphenoxy)piperidin-1-yl]sulphonyl}-1-phenylethyl(hydroxy)formamide

- (R/S)-hydroxy(1-phenyl-2-([4-(2-piperidin-1-ylphenoxy)piperidin-1-yl]sulphonyl)ethyl)formamide;
 (R/S)-2-([4-(4-fluoro-2-thien-3-ylphenoxy)piperidin-1-yl]sulphonyl)methyl)-N-hydroxy-4-methylpentanamide; and
 5 (R/S)- 2-([4-(4-fluoro-2-pyridin-3-ylphenoxy)piperidin-1-yl]sulphonyl)methyl)-N-hydroxy-4-methylpentanamide.

In another aspect the present invention provides a process for the preparation of a compound of formula (1) or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester
 10 thereof wherein Z is -N(OH)CHO, which process comprises the steps of:

- a) converting a hydroxylamine of formula (2) into a compound of formula (1);



Scheme 1

and thereafter if necessary:


- 15 i) converting a compound of formula (1) into another compound of formula (1);
 ii) removing any protecting groups;
 iii) forming a pharmaceutically acceptable salt or *in vivo* hydrolysable ester.

Formylation may be suitably performed by adding a preformed mixture of acetic acid (8 equivalents) and formic acid (excess) to formula (2) in tetrahydrofuran or dichloromethane
 20 and stirring the solution for 15 hours at temperatures ranging from 0°C to room temperature followed by stirring in methanol. Alternatively a formylation method described in *J. Med. Chem.*, 2002, 45, 219 using trifluoroethylformate can be used.

This process may further comprise a process for the preparation of a hydroxylamine of formula (2):

- 25 • when n is 0 and R⁴ is hydrogen (indicated as a compound of formula (2')), which process comprises:
 b) - converting an alkene of formula (3) into a hydroxylamine of formula (2') ;


-27-



Scheme 2

Suitable reagents for such a conversion include aqueous hydroxylamine in tetrahydrofuran under an argon atmosphere.


- 5 The alkene of formula (3) where R⁸ is hydrogen can be prepared by the reaction of a compound of formula (4') with a compound of formula (5) under Wadsworth-Emmons or Peterson reaction conditions;



Scheme 3

- 10 Wadsworth-Emmons or Peterson reactions involve the forming of the anion of formula (4') with 2 equivalents of lithium bis(trimethylsilyl)amide or sodium hydride or lithium diisopropylamide in tetrahydrofuran at temperatures of -78°C to 0°C and reacting this with 1 equivalent of diethylchlorophosphate (Wadsworth Emmons) or 1 equivalent of trimethylsilyl chloride (Peterson). After 1 hour an aldehyde (1.1 equivalent) in tetrahydrofuran is added to
- 15 the resultant anion described and reacted at room temperature over 15h.

The alkene of formula (3) can also be prepared by the reaction of a compound of formula (4') with a compound of formula (6) as illustrated by scheme 4;




Scheme 4

Suitable bases include lithium bis(trimethylsilyl)amide, sodium hydride or lithium diisopropyl amide in tetrahydrofuran at temperatures of -78°C to 0°C to form the anion. Suitable reducing agents for the reduction step include sodium borohydride in ethanol or borane-dimethylsulphide complex or borane-tetrahydrofuran complex in tetrahydrofuran at room temperature. Suitable dehydration reagents for the dehydration step include methanesulphonyl chloride or tosyl chloride and triethylamine in dichloromethane at room temperature.

Or a process for the preparation of a hydroxylamine of formula (2[#]):


- when n is 0 (indicated as a compound of formula (2[#])) may comprise:
 - c)
 - i) reacting a compound of formula (4'') (see scheme 13 for its preparation) with R^1COOR , R^1COCl or activated R^1COOR to yield a ketone of formula (7'') (where R is $\text{C}_{1-20}\text{alkyl}$ e.g. methyl, ethyl or $\text{arylC}_{1-4}\text{alkyl}$ e.g. benzyl);
 - ii) reducing the ketone of formula (7'') to yield an alcohol of formula (8'');
 - iii) converting $-\text{OH}$ group of the alcohol of formula (8'') into a leaving group (L) such as a halide, mesylate, tosylate etc. (see compound of formula (9''));
 - iv) displacing the leaving group with aqueous hydroxylamine to yield a hydroxylamine of formula (2[#]);



Scheme 5

A ketone of formula (7'') may additionally be prepared by the process illustrated in scheme 6:

-29-




Scheme 6

The silyl group present in the compound of formula (30) can be removed by tetrabutylammonium fluoride. Suitable leaving groups (L) are halo, mesyl and tosyl. A suitable chlorinating agent is POCl₃. A compound of formula (7'') is prepared in the last stage by reacting the compound of formula (33) with the appropriate piperidine reagent.

Or a process for the preparation of a hydroxylamine of formula (2):

- when n is 1 and R³ and R⁴ are both hydrogen (indicated as a compound of formula (2**)) may further comprise:
 - 10 d) i) reacting a compound of formula (4'') with a compound of formula (10) (either an epoxide or equivalent) to yield an alcohol of formula (8**);
 - ii) converting -OH group of the alcohol of formula (8**) into a leaving group such as a halide, mesylate, tosylate etc. (see compound of formula (9**);
 - 15 iii) displacing the leaving group with aqueous hydroxylamine to yield a hydroxylamine of formula (2**);

-30-




Scheme 7

Suitable bases are lithium bis(trimethylsilyl)amide and lithium diisopropylamide at temperatures from -78°C to 0°C . Suitable leaving groups (L) are chloro, bromo, iodo, methanesulphonyl and tosyl and these would be formed from the alcohol by treatment with methanesulphonyl chloride and pyridine in dichloromethane (mesylate), tosyl chloride and pyridine in dichloromethane (tosylate), triphenylphosphine and carbon tetrabromide (bromo); the chloro, bromo and iodo derivatives could also be prepared from the mesylate or tosylate by addition of a suitable halide source, e.g. tetrabutylammonium iodide or sodium iodide or lithium chloride in a solvent such as acetone.

Or a process for the preparation of a hydroxylamine of formula (2):

- when n is 1, indicated as a compound of formula (2[^]), may further comprise:
 - e) i) reacting a compound of formula (4'') with a compound of formula (11) to yield an ester of formula (12[^]);
 - 15 ii) converting the ester of formula (12[^]) into an alcohol of formula (13[^]);
 - iii) displacing the -OH group with aqueous hydroxylamine to yield a hydroxylamine of formula (2[^]);

-31-




Scheme 8

The group -COOR of formula (12^A) is representative of an ester wherein R may be C₁₋₂₀ alkyl, e.g. methyl, ethyl or arylC₁₋₄alkyl, e.g. benzyl. Baeyer-Villiger reaction conditions such as a peracid e.g. *m*-CPBA (3-chloroperoxybenzoic acid) in dichloromethane are suitable for the conversion of the ester group into the alcohol group. It may be appropriate to convert the alcohol group into a leaving group such as bromo, iodo, mesyl and tosyl, before displacement with aqueous hydroxylamine.

In another aspect the present invention provides a process for the preparation of a compound of formula (1) or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof wherein Z is -CONR¹⁵OH, which process comprises:

a) converting an acid of formula (14) into a compound of formula (1);



Scheme 9

and thereafter if necessary:

- i) converting a compound of formula (1) into another compound of formula (1);
- ii) removing any protecting groups;
- iii) forming a pharmaceutically acceptable salt or *in vivo* hydrolysable ester.


The acid of formula (14) may be suitably activated by conversion to an acid halide, such as the acid chloride or to an activated ester using carbonyldiimidazole, a carbodiimide or a

-32-

pentafluorophenyl ester. Alternatively when the acid of formula (14) is an ester e.g. the methyl or ethyl ester, it can be converted directly to a compound of formula (1) by reaction with NHR^{15}OH .

Also provided is a process for the preparation of an acid of formula (14) which process comprises;

- b) reacting a compound of formula (4'') with an alkene of formula (11) to yield an ester of formula (12[^]) which is hydrolysed to an acid of formula (14') where an acid of formula (14') is an acid of formula (14) wherein n is 1 and R^8 is hydrogen;




Scheme 10

Suitable bases able to deprotonate a compound of formula (4'') include butyllithium, lithium diisopropylamide and lithium bis(trimethylsilyl)amide followed by the addition of a copper salt e.g. copper-bromide-dimethylsulphide complex, copper iodide, in solvents such as dimethylsulphide, ether or tetrahydrofuran at temperatures from -78°C to room temperature.

Or a process for the preparation of an acid of formula (14) comprises;

- c) reacting a compound of formula (4'') with a compound of formula (15) to yield an acid of formula (14**) which is an acid of formula (14) wherein n is 0, R^3 is hydrogen and R^4 is hydrogen;




Scheme 11

Suitable bases to deprotonate formula (4'') include lithium diisopropylamide, lithium bis(trimethylsilyl)amide and sodium hydride in solvents such as tetrahydrofuran or ether at temperatures from -78°C to 0°C .

In another aspect the present invention provides a process for the preparation of a compound of formula (1) or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof wherein Z is $-\text{CONR}^{15}\text{OH}$, R^8 is hydrogen and n is 0, which process comprises steps

5 as outlined in scheme 12:



Scheme 12

The process of scheme 12 comprises the steps of:

- 10 reacting a thiol of formula (22) with an acrylate of formula (23) at temperatures of 0°C to 70°C to yield a thioether of formula (24);
- oxidising the thioether of formula (24) to a sulphonyl chloride of formula (25) by bubbling chlorine gas onto a solution of the thioether in acetic acid at temperatures of 0°C to room temperature;
- 15 reacting the sulphonyl chloride of formula (25) with a piperidine of formula (26) under standard sulphonamide conditions (e.g. triethylamine in DCM at temperatures from 0°C to 50°C) to yield a compound of formula (27);
- removing the protecting group to yield a compound of formula (1).

The protecting group (PG) may be benzyl or 2,4-dimethoxybenzyl. The former can be removed by treatment with hydrogen/ palladium and the latter by treatment with mild acid


(see Tetrahedron Letters, 1998, 39(43), 7865). The process of scheme 12 may further comprise if necessary:

- v) converting a compound of formula (1) into another compound of formula (1);
- vi) removing any other protecting groups;
- 5 vii) forming a pharmaceutically acceptable salt or *in vivo* hydrolysable ester.

In another aspect of the invention, there is provided a process for the preparation of compounds of formula (4), formula (4') and formula (4'') which process comprises;

- i) reacting a compound of formula (16) where B is an activate halo heterocyclyl with
10 a compound of formula (17) (wherein X is O or S), in the presence of a base to deprotonate the compound of formula (17), to yield a compound of formula (18);
- ii) removing the protecting group (PG) from the compound of formula (18) to yield a compound of formula (19);
- iii) reacting the compound of formula (19) with a suitable reagent to yield a
15 compound of formula (4); and
- iv) oxidising X where X is S as required.

When R⁴ is hydrogen a compound of formula (4') is produced and when R³ and R⁴ are both hydrogen compound of formula (4'') is produced;



Scheme 13


Compounds of formula (4), formula (4') and formula (4'') may also be prepared by a process which comprises;

- i) reacting a compound of formula (20) (wherein X is O or S) with a compound of
formula (21), in the presences of a base to yield a compound of formula (18);

-35-

- ii) removing the protecting group (PG) from the compound of formula (18) to yield a compound of formula (19);
- iii) reacting the compound of formula (19) with a suitable reagent to yield a compound of formula (4); and
- 5 iv) oxidising X as required.

When R^4 is hydrogen a compound of formula (4') is produced and when R^3 and R^4 are both hydrogen compound of formula (4'') is produced;




Scheme 14

- 10 In both schemes 13 and 14: L is a suitable leaving group such as halo (chloro, bromo, iodo), hydroxy, mesyl and tosyl; suitable bases to deprotonate compounds of formula (17) and formula (20) include sodium hydride, lithium diisopropylamide, lithium bis(trimethylsilyl)amide and butyllithium; suitable reaction conditions for a) are temperatures ranging from -78°C to 70°C and an aprotic solvent, e.g. tetrahydrofuran under argon; suitable
- 15 protecting groups (PG) include Boc (t-butoxycarbonyl), CBz (carbonyloxybenzyl) groups and mesyl or another alkylsulphonyl. In the case where PG is alkylsulphonyl, reaction of formula (16) and (17) and of formula (20) and formula (21) directly produces a compound of formula (4). A compound of formula (18) can be converted to formula (19) by treatment with acid (Boc) or hydrogen/ palladium (CBz). A compound of formula (19) can be converted to a
- 20 compound of formula (4) by treatment with an alkylsulphonyl chloride in the presence of a base such as pyridine in a solvent such as dichloromethane. When B is aromatic, X is O and L is OH, Mitsunobu conditions can be used to form a compound of formula (18), i.e. a compound of formula (16) or formula (20) would be reacted with a mixture of diethyl azodicarboxylate or diisopropylazodicarboxylate and triphenylphosphine and formula (17) or
- 25 formula (21) to give a compound of formula (4). In addition PG could also be a protected

hydroxamic acid or reverse hydroxamate. Thus reaction of formula (16) and (17) and of formula (20) and (21) would deliver a protected version of formula (1) which could then be deprotected.

- 5 A compound of formula (1) can be prepared by removal of a protecting group on the zinc binding group directly. The protecting group (PG) can be benzyl or 2,4-dimethoxybenzyl. The former can be removed by treatment with hydrogen/ palladium and the latter by treatment with mild acid (see Tetrahedron Letters, 1998, 39(43), 7865). The required protected hydroxamic acid or reverse hydroxamate can be obtained by using a suitably
- 10 protected hydroxylamine earlier in the synthesis.



Scheme 15

- 15 It will be appreciated that certain of the various ring substituents in the compounds of the present invention may be introduced by standard aromatic substitution reactions or generated by conventional functional group modifications either prior to or immediately following the processes mentioned above, and as such are included in the process aspect of the invention. Such reactions and modifications include, for example, introduction of a
- 20 substituent by means of an aromatic substitution reaction, reduction of substituents, alkylation of substituents and oxidation of substituents. The reagents and reaction conditions for such procedures are well known in the chemical art. Particular examples of aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as
- 25 aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; and the introduction of a halogen group. Particular examples of modifications

include the reduction of a nitro group to an amino group by for example, catalytic hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heating; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl.

It will also be appreciated that in some of the reactions mentioned herein it may be
5 necessary/desirable to protect any sensitive groups in the compounds. The instances where protection is necessary or desirable and suitable methods for protection are known to those skilled in the art. Conventional protecting groups may be used in accordance with standard practice (for illustration see T.W. Green, *Protective Groups in Organic Synthesis*, John Wiley and Sons, 1991). Thus, if reactants include groups such as amino, carboxy or hydroxy it may
10 be desirable to protect the group in some of the reactions mentioned herein.

A suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or *tert*-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The
15 deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a *tert*-butoxycarbonyl group may be removed, for example, by treatment with a
20 suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment
25 with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.

A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl
30 group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.

Alternatively an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis
5 with a base such as sodium hydroxide, or for example a *tert*-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

The protecting groups may be removed at any convenient stage in the synthesis using
10 conventional techniques well known in the chemical art.

As stated hereinbefore the compounds defined in the present invention possesses metalloproteinases inhibitory activity, and in particular TACE inhibitory activity. This property may be assessed, for example, using the procedure set out below.

15 Isolated Enzyme Assays

Matrix Metalloproteinase family including for example MMP13.

Recombinant human proMMP13 may be expressed and purified as described by Knauper *et al.* [V. Knauper *et al.*, (1996) *The Biochemical Journal* 271:1544-1550 (1996)].
The purified enzyme may be used to monitor inhibitors of activity as follows: purified
20 proMMP13 is activated using 1mM amino phenyl mercuric acid (APMA), 20 hours at 21°C; the activated MMP13 (11.25ng per assay) is incubated for 4-5 hours at 35°C in assay buffer (0.1M Tris-HCl, pH 7.5 containing 0.1M NaCl, 20mM CaCl₂, 0.02 mM ZnCl and 0.05% (w/v) Brij 35 using the synthetic substrate 7-methoxycoumarin-4-yl)acetyl.Pro.Leu.Gly.Leu.N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl.Ala.Arg.NH₂ in
25 the presence or absence of inhibitors. Activity is determined by measuring the fluorescence at λ_{ex} 328nm and λ_{em} 393nm. Percent inhibition may be calculated as follows: % Inhibition is equal to the $[\text{Fluorescence}_{\text{plus inhibitor}} - \text{Fluorescence}_{\text{background}}]$ divided by the $[\text{Fluorescence}_{\text{minus inhibitor}} - \text{Fluorescence}_{\text{background}}]$.

A similar protocol can be used for other expressed and purified pro MMPs using
30 substrates and buffers conditions optimal for the particular MMP, for instance as described in C. Graham Knight *et al.*, (1992) *FEBS Lett.* 296(3):263-266.

Adamalysin family including for example TNF convertase

The ability of the compounds to inhibit proTNF α convertase enzyme (TACE) has been assessed using a partially purified, isolated enzyme assay, the enzyme being obtained from the membranes of THP-1 as described by K. M. Mohler *et al.*, (1994) Nature 370:218-220. The

5 purified enzyme activity and inhibition thereof was determined by incubating the partially purified enzyme in the presence or absence of test compounds using the substrate 4',5'-Dimethoxy-fluoresceinyl Ser.Pro.Leu.Ala.Gln.Ala.Val.Arg.Ser.Ser.Ser.Arg.Cys(4-(3-succinimid-1-yl)-fluorescein)-NH₂ in assay buffer (50mM Tris HCl, pH 7.4 containing 0.1% (w/v) Triton X-100 and 2mM CaCl₂), at 26°C for 4 hours. The amount of inhibition was

10 determined as for MMP13 except λ_{ex} 485nm and λ_{em} 538nm were used. The substrate was synthesised as follows. The peptidic part of the substrate was assembled on Fmoc-NH-Rink-MBHA-polystyrene resin either manually or on an automated peptide synthesiser by standard methods involving the use of Fmoc-amino acids and O-benzotriazol-1-yl-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU) as coupling agent with at least a 4- or 5-

15 fold excess of Fmoc-amino acid and HBTU. Ser¹ and Pro² were double-coupled. The following side chain protection strategy was employed; Ser¹(But), Gln⁵(Trityl), Arg^{8,12}(Pmc or Pbf), Ser^{9,10,11}(Trityl), Cys¹³(Trityl). Following assembly, the N-terminal Fmoc-protecting group was removed by treating the Fmoc-peptidyl-resin with in DMF. The amino-peptidyl-resin so obtained was acylated by treatment for 1.5-2hr at 70°C with 1.5-2 equivalents of 4',5'-

20 dimethoxy-fluorescein-4(5)-carboxylic acid [Khanna & Ullman, (1980) Anal Biochem. 108:156-161) which had been preactivated with diisopropylcarbodiimide and 1-hydroxybenzotriazole in DMF]. The dimethoxyfluoresceinyl-peptide was then simultaneously deprotected and cleaved from the resin by treatment with trifluoroacetic acid containing 5% each of water and triethylsilane. The dimethoxyfluoresceinyl-peptide was isolated by

25 evaporation, trituration with diethyl ether and filtration. The isolated peptide was reacted with 4-(N-maleimido)-fluorescein in DMF containing diisopropylethylamine, the product purified by RP-HPLC and finally isolated by freeze-drying from aqueous acetic acid. The product was characterised by MALDI-TOF MS and amino acid analysis.

The compounds of the invention have been found to be active against TACE at 0.1nM

30 to 50 μ M and in particular 10 μ M of compound 8 gave 81% inhibition and 10 μ M of compound 14 gave 76% inhibition.

Natural Substrates

The activity of the compounds of the invention as inhibitors of aggrecan degradation may be assayed using methods for example based on the disclosures of E. C. Arner *et al.*, (1998) *Osteoarthritis and Cartilage* 6:214-228; (1999) *Journal of Biological Chemistry*, 274 5 (10), 6594-6601 and the antibodies described therein. The potency of compounds to act as inhibitors against collagenases can be determined as described by T. Cawston and A. Barrett (1979) *Anal. Biochem.* 99:340-345.

Inhibition of metalloproteinase activity in cell/tissue based activity

10 Test as an agent to inhibit membrane sheddases such as TNF convertase

The ability of the compounds of this invention to inhibit the cellular processing of TNF α production may be assessed in THP-1 cells using an ELISA to detect released TNF essentially as described K. M. Mohler *et al.*, (1994) *Nature* 370:218-220. In a similar fashion the processing or shedding of other membrane molecules such as those described in N. M. 15 Hooper *et al.*, (1997) *Biochem. J.* 321:265-279 may be tested using appropriate cell lines and with suitable antibodies to detect the shed protein.

Test as an agent to inhibit cell based invasion

The ability of the compound of this invention to inhibit the migration of cells in an invasion assay may be determined as described in A. Albini *et al.*, (1987) *Cancer Research* 20 47:3239-3245.

Test as an agent to inhibit whole blood TNF sheddase activity

The ability of the compounds of this invention to inhibit TNF α production is assessed in a human whole blood assay where LPS is used to stimulate the release of TNF α . 160 μ l of heparinized (10Units/ml) human blood obtained from volunteers, was added to the plate and 25 incubated with 20 μ l of test compound (duplicates), in RPMI1640 + bicarbonate, penicillin, streptomycin, glutamine and 1% DMSO, for 30 minutes at 37°C in a humidified (5%CO₂/95%air) incubator, prior to addition of 20 μ l LPS (E. coli. 0111:B4; final concentration 10 μ g/ml). Each assay includes controls of neat blood incubated with medium alone or LPS (6 wells/plate of each). The plates are then incubated for 6 hours at 37°C 30 (humidified incubator), centrifuged (2000rpm for 10 min; 4°C), plasma harvested (50-100 μ l) and stored in 96 well plates at -70°C before subsequent analysis for TNF α concentration by ELISA.

Test as an agent to inhibit in vitro cartilage degradation

The ability of the compounds of this invention to inhibit the degradation of the aggrecan or collagen components of cartilage can be assessed essentially as described by K. M. Bottomley *et al.*, (1997) *Biochem J.* 323:483-488.

5

In vivo assessment**Test as an anti-TNF agent**

The ability of the compounds of this invention as *in vivo* TNF α inhibitors is assessed in the rat. Briefly, groups of female Wistar Alderley Park (AP) rats (90-100g) are dosed with
 10 compound (5 rats) or drug vehicle (5 rats) by the appropriate route e.g. peroral (p.o.), intraperitoneal (i.p.), subcutaneous (s.c.) 1 hour prior to lipopolysaccharide (LPS) challenge (30 μ g/rat i.v.). Sixty minutes following LPS challenge rats are anaesthetised and a terminal blood sample taken via the posterior vena cavae. Blood is allowed to clot at room temperature for 2 hours and serum samples obtained. These are stored at -20°C for TNF α ELISA and
 15 compound concentration analysis.

Data analysis by dedicated software calculates for each compound/dose:

$$\text{Percent inhibition of TNF}\alpha = \frac{\text{Mean TNF}\alpha (\text{Vehicle control}) - \text{Mean TNF}\alpha (\text{Treated}) \times 100}{\text{Mean TNF}\alpha (\text{Vehicle control})}$$

Test as an anti-arthritic agent

20 Activity of a compound as an anti-arthritic is tested in the collagen-induced arthritis (CIA) as defined by D. E. Trentham *et al.*, (1977) *J. Exp. Med.* 146:857. In this model acid soluble native type II collagen causes polyarthritis in rats when administered in Freund's incomplete adjuvant. Similar conditions can be used to induce arthritis in mice and primates.

25 Pharmaceutical Compositions

According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of formula (1), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore in association with a pharmaceutically-acceptable diluent or carrier.

30 The composition may be in a form suitable for oral administration, for example as a tablet or capsule, for parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) as a sterile solution, suspension or emulsion, for topical

administration as an ointment or cream or for rectal administration as a suppository. The composition may also be a form suitable for inhalation

In general the above compositions may be prepared in a conventional manner using conventional excipients.

5 The pharmaceutical compositions of this invention will normally be administered to humans so that, for example, a daily dose of 0.5 to 75 mg/kg body weight (and preferably 0.5 to 30 mg/kg body weight) is received. This daily dose may be given in divided doses as necessary, the precise amount of the compound received and the route of administration depending on the weight, age and sex of the patient being treated and on the particular disease
10 condition being treated according to principles known in the art.

Typically unit dosage forms will contain about 1 mg to 500 mg of a compound of this invention.

Therefore in a further aspect of the present invention there is provided a compound of formula (1), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as
15 defined hereinbefore, for use in a method of treatment of a warm-blooded animal such as man by therapy.

Also provided is a compound of formula (1), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore, for use in a method of treating a disease condition mediated by one or more metalloproteinase enzymes and in particular a
20 disease condition mediated by TNF α .

Further provided is a compound of formula (1), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore, for use in a method of treating inflammatory diseases, autoimmune diseases, allergic/atopic diseases, transplant rejection, graft versus host disease, cardiovascular disease, reperfusion injury and malignancy in a
25 warm-blooded animal such as man. In particular a compound of formula (1), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore, is provided for use in a method of treating rheumatoid arthritis, Crohn's disease and psoriasis, and especially rheumatoid arthritis. A compound of formula (1), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore, is also provided
30 for use in a method of treating a respiratory disorder such as asthma or COPD.

According to an additional aspect of the invention there is provided a compound of formula (1), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore, for use as a medicament.

Also provided is a compound of formula (1), or a pharmaceutically acceptable salt or
5 *in vivo* hydrolysable ester thereof, as defined hereinbefore, for use as a medicament in the treatment of a disease condition mediated by one or more metalloproteinase enzymes and in particular a disease condition mediated by TNF α .

Further provided is a compound of formula (1), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore, for use as a medicament in the
10 treatment of inflammatory diseases, autoimmune diseases, allergic/atopic diseases, transplant rejection, graft versus host disease, cardiovascular disease, reperfusion injury and malignancy in a warm-blooded animal such as man. In particular a compound of formula (1); or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore, is provided for use as a medicament in the treatment of rheumatoid arthritis, Crohn's disease
15 and psoriasis, and especially rheumatoid arthritis. A compound of formula (1), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore, is also provided for use as a medicament in the treatment of a respiratory disorder such as asthma or COPD.

According to this another aspect of the invention there is provided the use of a
20 compound of formula (1), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore in the manufacture of a medicament for use in the treatment of a disease condition mediated by one or more metalloproteinase enzymes and in particular a disease condition mediated by TNF α in a warm-blooded animal such as man.

Also provided is the use of a compound of formula (1), or a pharmaceutically
25 acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore in the manufacture of a medicament for use in the treatment of inflammatory diseases, autoimmune diseases, allergic/atopic diseases, transplant rejection, graft versus host disease, cardiovascular disease, reperfusion injury and malignancy in a warm-blooded animal such as man. In particular the use of a compound of formula (1), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore, is provided in the manufacture of a
30 medicament in the treatment of rheumatoid arthritis, Crohn's disease and psoriasis, and especially rheumatoid arthritis. The use of a compound of formula (1), or a pharmaceutically

acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore, is provided in the manufacture of a medicament in the treatment of a respiratory disorder such as asthma or COPD.

According to a further feature of this aspect of the invention there is provided a
5 method of producing a metalloproteinase inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1).

According to a further feature of this aspect of the invention there is provided a
method of producing a TACE inhibitory effect in a warm-blooded animal, such as man, in
10 need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1).

According to this further feature of this aspect of the invention there is provided a
method of treating autoimmune disease, allergic/atopic diseases, transplant rejection, graft
versus host disease, cardiovascular disease, reperfusion injury and malignancy in a
15 warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1).

Also provided is a method of treating rheumatoid arthritis, Crohn's disease and
psoriasis, and especially rheumatoid arthritis in a warm-blooded animal, such as man, in need
of such treatment which comprises administering to said animal an effective amount of a
20 compound of formula (1). Further provided is a method of treating a respiratory disorder such as asthma or COPD in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1).

In addition to their use in therapeutic medicine, the compounds of formula (1) and
their pharmaceutically acceptable salts are also useful as pharmacological tools in the
25 development and standardisation of *in vitro* and *in vivo* test systems for the evaluation of the effects of inhibitors of cell cycle activity in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.

In the above other pharmaceutical composition, process, method, use and medicament
manufacture features, the alternative and preferred embodiments of the compounds of the
30 invention described herein also apply.

Examples

The invention will now be illustrated by the following non-limiting examples in which, unless stated otherwise:

- (i) temperatures are given in degrees Celsius (°C); operations were carried out at room or ambient temperature, that is, at a temperature in the range of 18-25°C;
- (ii) organic solutions were dried over anhydrous magnesium sulphate; evaporation of solvent was carried out using a rotary evaporator under reduced pressure (600-4000 Pascals; 4.5-30 mm Hg) with a bath temperature of up to 60°C;
- (iii) chromatography unless otherwise stated means flash chromatography on silica gel; thin layer chromatography (TLC) was carried out on silica gel plates; where a "Bond Elut" column is referred to, this means a column containing 10g or 20g of silica of 40 micron particle size, the silica being contained in a 60ml disposable syringe and supported by a porous disc, obtained from Varian, Harbor City, California, USA under the name "Mega Bond Elut SI". Where an "IsoluteTM SCX column" is referred to, this means a column containing benzenesulphonic acid (non-endcapped) obtained from International Sorbent Technology Ltd., 1st House, Duffryn Industrial Estate, Ystrad Mynach, Hengoed, Mid Glamorgan, UK. Where Flashmaster II is referred to, this means a UV driven automated chromatography unit supplied by Jones;
- (iv) in general, the course of reactions was followed by TLC and reaction times are given for illustration only;
- (v) yields, when given, are for illustration only and are not necessarily those which can be obtained by diligent process development; preparations were repeated if more material was required;
- (vi) when given, ¹H NMR data is quoted and is in the form of delta values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard, determined at 300 MHz using perdeuterio DMSO (CD₃SOCD₃) as the solvent unless otherwise stated; coupling constants (J) are given in Hz;
- (vii) chemical symbols have their usual meanings; SI units and symbols are used;
- (viii) solvent ratios are given in percentage by volume;
- (ix) mass spectra (MS) were run with an electron energy of 70 electron volts in the chemical ionisation (APCI) mode using a direct exposure probe; where indicated ionisation was effected by electrospray (ES); where values for m/z are given, generally only ions which

indicate the parent mass are reported, and unless otherwise stated the mass ion quoted is the positive mass ion - $(M+H)^+$;

(x) LCMS characterisation was performed using a pair of Gilson 306 pumps with Gilson 233 XL sampler and Waters ZMD4000 mass spectrometer. The LC comprised water symmetry
 5 4.6x50 column C18 with 5 micron particle size. The eluents were: A, water with 0.05% formic acid and B, acetonitrile with 0.05% formic acid. The eluent gradient went from 95% A to 95% B in 6 minutes. Where indicated ionisation was effected by electrospray (ES); where values for m/z are given, generally only ions which indicate the parent mass are reported, and unless otherwise stated the mass ion quoted is the positive mass ion - $(M+H)^+$ and

10 (xi) the following abbreviations are used:-----


	DMSO	dimethyl sulphoxide;
	DMF	N-dimethylformamide;
	DCM	dichloromethane;
	NMP	N-methylpyrrolidinone;
15	DIAD	di-isopropylazodicarboxylate
	LHMDS or LiHMDS	lithium bis(trimethylsilyl)amide
	MeOH	methanol
	RT	room temperature
	TFA	trifluoroacetic acid
20	EtOH	ethanol
	EtOAc	ethyl acetate
	Et ₂ O	diethylether
	THF	tetrahydrofuran
	TBDMS	tertiarybutyldimethylsilyl
25	DIPEA	diisopropylethylamine
	MTBE	methyltertiarybutylether

The invention will now be illustrated but not limited by the following Examples:

30. EXAMPLE 1

(R/S)- 2-{{[4-(2-isoxazol-5-ylphenoxy)piperidin-1-yl]sulphonyl}-1-phenylethyl(hydroxy)formamide

-47-



5

To a solution of (R/S)-2-{{[4-(2-isoxazol-5-ylphenoxy)piperidin-1-yl]sulphonyl}-1-phenylethyl(hydroxylamine) (described below) (330mg, 0.75mmol) in DCM (0.5ml) was added a pre-mixture of formic acid (2ml) and acetic anhydride (1ml) and the reaction stirred at RT overnight. MeOH (5ml) was then added and the mixture stirred at RT for 1 hour. After
 10 evaporation the residues were re-dissolved in MeOH and stirred for 3 hours before re-
 evaporation. The residue was purified by BondElut chromatography, eluting with a gradient
 from DCM to 5% methanol in DCM to give (R/S)-2-{{[4-(2-isoxazol-5-ylphenoxy)piperidin-1-
 yl]sulphonyl}-1-phenylethyl(hydroxy)formamide (88mg, 0.19mmol). MS: 472.

15 The starting (R/S)-2-{{[4-(2-isoxazol-5-ylphenoxy)piperidin-1-yl]sulphonyl}-1-
 phenylethyl(hydroxylamine) was prepared as follows:


- i. Triethylamine (8.0g, 0.079mol) was added to a stirred solution of *E*- β -styrenesulphonyl chloride (12.0g, 0.059mol) and 4-hydroxypiperidine (8.0g, 0.079mol) in THF (100ml) at RT. Stirring was continued overnight before the reaction mixture was
 20 reduced to low volume and partitioned between EtOAc followed by aqueous 1M HCl,
 saturated NaHCO₃ and brine. The organic fraction was then dried (Na₂SO₄) and evaporated to
 give a solid product. (12.75g; 0.046mol); NMR (CDCl₃): 1.5–1.8 (m, 4H), 1.9–2.1 (m, 2H),
 3.0–3.2 (m, 2H), 3.4–3.6 (m, 2H), 3.85 (s, 1H), 6.65 (s, 1H), 7.3–7.6 (m, 6H); MS: 268.
- ii. 2-(5-Isoxazolyl)-phenol (121mg, 0.75mmol) was dissolved in DCM (1ml) and *E*-1-(4-
 25 hydroxypiperidin-1-ylsulphonyl)-2-phenylethene (0.2g, 0.75mmol) was added. A solution of
 triphenylphosphine (0.2g, 0.75mmol) in DCM (2ml) followed by a solution of DIAD (0.15ml,
 0.75mmol) in DCM (2ml) was then added and the resulting mixture stirred at RT overnight.
 The mixture was concentrated and purified by chromatography: bond elute cartridge, eluent
 hexane (5 minutes; 20 ml/minute), 100% hexane to 100% DCM (15 minutes) to give *E*-[4-(2-
 30 (5-isoxazolyl)phenoxy)piperidin-1-ylsulphonyl]-2-phenylethene, which was carried through
 to the next step.

-48-

iii. *E*-[4-(2-(5-isoxazolyl)phenoxy)piperidin-1-ylsulphonyl]-2-phenylethene, was dissolved in THF (1ml) and the air in the tubes excluded with argon before hydroxylamine in water (50% solution, 1ml) was added and the mixture stirred vigorously overnight. EtOAc (1ml) was added and the aqueous layer separated. The organic layers were washed with brine
 5 and dried (Na_2SO_4) and concentrated to give (R/S)-2-[[4-(2-isoxazol-5-ylphenoxy)piperidin-1-yl]sulphonyl]-1-phenylethyl(hydroxylamine) which was carried through to the final step.

EXAMPLE 2

(R/S)- 1-[[({4-[2-chloro-4-(trifluoromethyl)phenoxy]piperidin-1-yl} sulphonyl)methyl]-4-
 10 pyrimidin-2-ylbutyl(hydroxy)formamide



To formic acid (2.32 ml) at 0°C was added acetic anhydride (0.84 ml). After 20 minutes this was added to (R/S)-1-[[({4-[2-chloro-4-(trifluoromethyl)phenoxy]piperidin-1-yl} sulphonyl)methyl]-4-pyrimidin-2-ylbutyl(hydroxylamine) (0.67g, 1.28mmol) dissolved in
 15 THF (6.9 ml) and formic acid (2.32 ml) and the resulting solution stirred for 10 minutes. The solvent was removed *in vacuo* and the residue dissolved in DCM, washed with saturated sodium bicarbonate solution, dried and evaporated to dryness. The product was then re-dissolved in MeOH and stirred overnight. The solvent was removed *in vacuo* and the residue stirred in Et₂O to give (R/S)- 1-[[({4-[2-chloro-4-(trifluoromethyl)phenoxy]piperidin-1-yl} sulphonyl)methyl]-4-pyrimidin-2-ylbutyl(hydroxy)formamide as a white solid (0.19g,
 20 0.35mmol). NMR: (CDCl_3 , 300 MHz): 9.99 (s, 0.5H)*; 9.18 (brs, 0.5H)*; 8.70 (dd, 2H); 8.52 (s, 0.5H)*; 8.05 (s, 0.5H)*, 7.67 (s, 1H); 7.48 (d, 1H); 7.21 (t, 1H); 6.99 (d, 1H); 4.91 (m, 0.5H)*, 4.70 (bs, 1H); 4.23 (m, 0.5H)*; 3.63-3.27(m, 5H), 3.20-2.85 (m, 2H), 2.10-1.85 (m, 7H), 1.82-1.60(m, 3H); δC (CDCl_3 , 75.5 MHz):162.0, 157.6, 157.5, 157.4, 128.3, 125.4,
 25 119.3, 115.0, 72.2, 72.0, 56.1, 51.5, 51.4, 50.5, 42.1, 49.1, 41.7, 37.9, 37.3, 30.5, 30.3, 30.1, 28.6, 24.1, 23.8; MS: 551.42; HPLC: 5%-95% MeOH 10 minutes gradient: 9.088 m, 91.62%.

*rotameric signals

The starting (R/S)-1-[(4-[2-chloro-4-(trifluoromethyl)phenoxy]piperidin-1-yl)sulphonyl)methyl]-4-pyrimidin-2-ylbutyl(hydroxylamine) was prepared as follows:

- i. Diisopropyl azodicarboxylate (6.68 ml, 33mmol) was added dropwise to a solution of *tert*-butyl 4-hydroxypiperidine carboxylate (4.27g, 21.2mmol) and triphenyl phosphine (7.78g, 29.7mmol) in toluene (160 ml) at 0°C under argon. The mixture was stirred for ½ hour, 2-chloro-4-trifluoromethylphenol (5.00g, 25.5mmol) was then added dropwise and the reaction allowed to warm to RT overnight. The solvent was removed *in vacuo* and the residue stirred in isohexane for 1 hour. The precipitate was filtered off and the filtrate concentrated to an orange oil which was purified by flash column chromatography (10% EtOAc in isohexane) to afford 1-*tert*-butyl-4-(2-chloro-4-trifluoromethylphenoxy)piperidine carboxylate (4.59g, 12mmol). NMR: (CDCl₃, 300 MHz): 7.68 (s, 1H); 7.46 (d, 1H); 6.98 (d, 1H); 4.68 (m, 1H); 3.69-3.44 (m, 4H); 1.79-1.92 (m, 4H); 1.46 (s, 9H).
- ii. TFA (11.76 ml) was added to a solution of 1-*tert*-butyl-4-(2-chloro-4-trifluoromethylphenoxy)piperidine carboxylate (4.59g, 12mmol) in DCM (23.5 ml) at 0°C and the solution stirred for 20 hours. The solvent was removed *in vacuo*, the residue taken up in 2M aqueous sodium hydroxide solution and water and then extracted into EtOAc. The organics were dried (MgSO₄) and concentrated to give 4-(2-chloro-4-trifluoromethylphenoxy)piperidine TFA salt as a white solid (4.47g, 11.4mmol). NMR (CDCl₃, 300 MHz): 7.66 (s, 1H); 7.50 (d, 1H); 7.00 (d, 1H); 4.83 (bs, 1H); 3.50-3.19 (m, 4H); 2.40-2.11 (m, 4H).
- iii. Methanesulphonyl chloride (1.36 ml) was added dropwise to a solution of 4-(2-chloro-4-trifluoromethylphenoxy)piperidine TFA salt (4.47g, 11.4mmol) in triethylamine (6.67 ml) and DCM (58 ml) at 0°C, under argon. The mixture was allowed to come to RT over a weekend. DCM was added to the reaction mixture, the organics were washed with water, dried (MgSO₄) and concentrated *in vacuo* to give 4-(2-chloro-4-trifluoromethylphenoxy)piperidin-1-ylsulphonylmethane as an oil (1.43g, 4mmol). NMR (CDCl₃, 300 MHz): 7.67 (s, 1H); 7.51 (d, 1H); 7.00 (d, 1H); 4.75 (m, 1H); 3.59-3.49 (m, 2H); 3.39-3.20 (m, 2H); 2.83 (s, 3H); 2.15-2.00 (m, 4H).
- iv. LHMDs (6.15 ml of a 1M solution in THF) was added dropwise to a solution of 4-(2-chloro-4-trifluoromethylphenoxy)piperidin-1-ylsulphonylmethane (1.00g, 2.8mmol) in THF (11 ml) at -10°C under argon. The mixture was stirred for 10 minutes and then trimethylsilyl chloride (0.36 ml) was added dropwise at -10°C. Stirring was continued for a further 20

-50-

minutes and then 4-(2-pyrimidinyl)butan-1-al§ (462mg, 3.1mmol) was added in THF (5 ml) again ensuring that the temperature did not exceed -10°C. The reaction mixture was stirred for 2 hours and then quenched with brine at -10°C. The solution was allowed to warm to RT, diluted with water and the aqueous layer extracted with EtOAc. The organics were dried (MgSO₄) and concentrated to a yellow oil, purified by flash column chromatography (5% MeOH in DCM) to afford *E/Z*-1-{4-(2-chloro-4-trifluoromethylphenoxy)piperidin-1-ylsulphonyl}-5-(pyrimidin-2-yl)pent-1-ene (0.64 g, 1.3mmol). NMR: (CDCl₃, 300 MHz): 8.67 (2x d overlaid, 2H)*; 7.64 (m, 1H); 7.46 (bd, 1H); 7.14 (m, 1H); 7.00 (dd, 1H); 6.80 (dt, 0.5H)*; 6.40 (dt, 0.5H)*; 6.18 (d, 0.5H)*; 6.05 (d, 0.5H)*; 4.70 (bs, 1H); 3.50-3.32 (m, 2H); 3.29-3.09 (m, 2H); 3.02 (dd, *J* = 7.7 Hz, *J* = 7.7 Hz, 2H, CH₂CH₂Ar); 2.73 (ddd, *J* = 14.9 Hz, *J* = 7.34 Hz, 1H, 1H); 2.39 (ddd, H); 2.10-1.95 (m, 6H); LCMS: 490.36 (M+H).

* cis/trans signals


v. Hydroxylamine solution (1.90 ml of a 50% aqueous solution) was added to a solution of *E/Z*-1-{4-(2-chloro-4-trifluoromethylphenoxy)piperidin-1-ylsulphonyl}-5-(pyrimidin-2-yl)pent-1-ene (0.64g, 1.3mmol) in THF (9.5 ml) at RT and the mixture stirred overnight. The solvent was reduced *in vacuo* and the residue partitioned between EtOAc and water. The aqueous layer was extracted with EtOAc and the organics dried (MgSO₄) before being concentrated to a yellow oil to give (R/S)-1-[(4-[2-chloro-4-(trifluoromethyl)phenoxy]piperidin-1-yl)sulphonyl)methyl]-4-pyrimidin-2-ylbutyl(hydroxylamine) (0.67g, 1.28mmol). NMR: (CDCl₃, 300 MHz): 8.64 (d, 2H); 7.65 (d, 1H); 7.48 (d, 1H); 7.16 (t, 1H); 7.00 (d, 1H); 4.75 (m, 1H); 3.60-3.32 (m, 6H); 3.17 (m, 1H); 3.03 (m, 1H); 2.85 (d, 1H); 2.15-1.50 (m, 7H).

§ 4-(2-pyrimidinyl)-butanal has been reported in the literature and has CAS registry number 260441-10-9 (CA Index Name: 2-pyrimidinebutanal).

25

EXAMPLE 3

(R/S)- 1-([(4-(2-bromo-4-fluorophenoxy)piperidin-1-yl)sulphonyl)methyl]-4-pyrimidin-2-ylbutyl(hydroxy)formamide









-51-





The procedure described in Example 2 was followed using 2-bromo-4-fluorophenol (4.78g, 25mmol) in place of 2-chloro-4-trifluoromethylphenol to give (R/S)- 1-([4-(2-bromo-4-fluorophenoxy)piperidin-1-yl]sulphonyl)methyl)-4-pyrimidin-2-ylbutyl(hydroxy)formamide (195mgs, 0.36mmol). NMR: 9.7 & 9.35 (d, 1H), 8.5 (d, 2H), 8.14 & 7.7 (d, 1H), 7.35 (m, 5 1H), 7.1 (t, 1H), 7.0 (m, 2H), 4.4 & 3.9 (br d, 1H), 2.9 (brm, 6H), 2.6 (t, 2H), 1.7 (m, 2H), 1.5 (m, 6H); MS: 545/ 547.

EXAMPLES 4-21





The procedure described in Example 1 was followed except that the 2-(5-isoxazolyl)-phenol
10 starting material used was replaced by the phenol described.





Example	Structure and name	Starting phenol	MH+
4	 <p>(R/S)-2-([4-(2-bromophenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide</p>	2-bromophenol	483
5	 <p>(R/S)-2-([4-(2-chlorophenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide</p>	2-chlorophenol	439

6	 <p>(R/S)-2-([4-(2-chloro-4-fluorophenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide</p>	2-chloro-4-fluorophenol	457
7	 <p>(R/S)-2-([4-(2,4-dichlorophenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide</p>	2,4-dichlorophenol	473
8	 <p>(R/S)-hydroxy(2-([4-(2-isopropoxyphenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl)formamide</p>	2-isopropoxy phenol	463
9	 <p>(R/S)-hydroxy(2-([4-(2-trifluoromethylphenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl)formamide</p>	2-trifluoromethyl phenol	473

	yl]sulphonyl}-1-phenylethyl)formamide		
10	 <p>(R/S)-2-([4-(4-chloro-2-nitrophenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide</p>	4-chloro-2-nitrophenol	484
11	 <p>(R/S)-hydroxy(2-([4-(4-methyl-2-nitrophenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl)formamide</p>	4-methyl-2-nitrophenol	464
12	 <p>(R/S)-2-([4-(2-bromo-4-fluorophenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide</p>	4-fluoro-2-bromophenol	501
13	 <p>(R/S)-hydroxy(2-([4-(2-methoxy-4-nitrophenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl)formamide</p>	2-methoxy-4-nitrophenol	480

-54-

14	 <p>(R/S)-hydroxy[2-((4-[2-isopropylaminocarbonyl]phenoxy)piperidin-1-yl)sulphonyl]-1-phenylethyl]formamide</p>	2-(isopropylamino carbonyl)-phenol	490
15	 <p>(R/S)-hydroxy(1-phenyl-2-[[4-(2-piperidin-1-ylphenoxy)piperidin-1-yl]sulphonyl]ethyl)formamide</p>	(2-piperidin-1-yl)phenol	488
16	 <p>(R/S)-2-[[4-(2-fluoro-4-nitrophenoxy)piperidin-1-yl]sulphonyl]-1-phenylethyl(hydroxy)formamide</p>	2-fluoro-4-nitrophenol	468
17	 <p>(R/S)-2-[[4-(2-chloro-4-methylphenoxy)piperidin-1-yl]sulphonyl]-1-phenylethyl(hydroxy)formamide</p>	2-chloro-4-methylphenol	453


	phenylethyl(hydroxy) formamide		
18	 <p>(R/S)-2-([4-(2-chloro-4-methoxyphenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide</p>	2-chloro-4-methoxyphenol	469
19	 <p>(R/S)-2-([4-(4-fluoro-2-methoxyphenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide</p>	4-fluoro-2-methoxyphenol	453
20	 <p>(R/S)-2-([4-(4-chloro-2-fluorophenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide</p>	4-chloro-2-fluorophenol	457
21		4-fluoro-2-methylphenol	437

-56-

	(R/S)-2-([4-(4-fluoro-2-methylphenoxy)piperidin-1-yl]sulphonyl)-1-phenylethyl(hydroxy)formamide		
--	---	--	--

EXAMPLE 22

(R/S)-2-([4-[(3-chloropyridin-2-yl)oxy]piperidin-1-yl]sulphonyl)-1-pyridin-3-ylethyl(hydroxy)formamide



5

(R/S)-2-([4-[(3-chloropyridin-2-yl)oxy]piperidin-1-yl]sulphonyl)-1-pyridin-3-ylethyl hydroxylamine (0.75mmol) (prepared below and used directly) was dissolved in DCM (1ml) and a preformed-mixture of acetic anhydride (1ml) and formic acid (2ml) was added before stirring at RT overnight. MeOH (5ml) was then added and, after stirring for 30 minutes; the mixture was evaporated. The residue was re-dissolved in MeOH (2ml) and allowed to stand at RT overnight. After evaporation the mixture was purified by BondElut chromatography (10g Silica), eluting with a gradient from DCM to 5% MeOH in DCM to give (R/S)-2-([4-[(3-chloropyridin-2-yl)oxy]piperidin-1-yl]sulphonyl)-1-pyridin-3-ylethyl(hydroxy)formamide (47mgs, 0.11mmol). MS: 441.

15

The starting (R/S)-2-([4-[(3-chloropyridin-2-yl)oxy]piperidin-1-yl]sulphonyl)-1-pyridin-3-ylethyl hydroxylamine was prepared as follows:

- i) A solution of 4-hydroxypiperidine (8g; 0.08mol) in DCM (80ml) was cooled in an ice bath before pyridine (7.4ml; 0.09mol) and TBDMS triflate (20ml; 0.088mol) were added. The resulting mixture was stirred for 2 ½ hours. Iced water was added and the organic layer separated, washed with brine, dried and evaporated to give 4-(*tert*-butyl dimethylsilyl)oxypiperidine as a pale yellow residue (24g).
- ii) Methanesulphonyl chloride (1.0ml; 0.012mol) was added to a solution of the 4-*tert*-butyl-dimethylsilyloxy-piperidine (2.7g; 0.012mol) and DIPEA (4.4ml; 0.025mol) in DCM (20ml) and the whole stirred at RT overnight. Water (20ml) was added and the organic layer

25

-57-

separated and washed with 2M hydrochloric acid, saturated sodium bicarbonate and brine and evaporated to give 1-methanesulphonyl-4-(*tert*-butyldimethylsilyloxy)piperidine as a black, oily residue.

- iii) A solution of 1-methanesulphonyl-4-(*tert*-butyldimethylsilyloxy)piperidine (2.0g; 6.8mmol) in THF (50ml) was covered with argon and cooled in an ice/ acetone bath before a solution of LHMDs in THF (15.0ml; 1M; 15.0mmol) was added dropwise. After stirring for 30 minutes, diethyl chlorophosphate (1.0ml; 6.8mmol) was added and stirring continued for a further 50 minutes. Nicotinaldehyde (0.64ml; 6.8mmol) was then added and the solution allowed to warm to ambient temperature and stirred overnight. A saturated solution of ammonium chloride was then added and the mixture extracted with ethyl acetate. The dried organic extracts were concentrated in vacuo. Purification was by chromatography on silica, eluting with a increasing gradient from hexane to 50% ethyl acetate in hexane to give *E*-[4-(*tert*-butyldimethylsilyloxy)piperidin-1-ylsulphonyl]-2-(3-pyridyl)ethene (1.93g, 5.05mmol).
- iv) *E*-[4-(*tert*-butyldimethylsilyloxy)piperidin-1-ylsulphonyl]-2-(3-pyridyl)ethene (1.93g; 5.05mmol) was added to a pre-mixture of acetyl chloride (2ml) in methanol (20ml) and stirred at room temperature for 2 hours. Concentration in vacuo gave a solid which was partitioned between saturated sodium bicarbonate and ethyl acetate. The organic extracts were dried and evaporated. Purification was by chromatography on silica (20g) eluting with a gradient from DCM to 20% methanol in DCM. Evaporation of fractions containing product gave *E*-[4-(hydroxy)piperidin-1-ylsulphonyl]-2-(3-pyridyl)ethene as a white solid (0.4g; 30%). NMR (400MHz): 1.4 (2H, m, CH₂); 1.8 (2H, m, CH₂); 2.9 (2H, m, CH₂); 3.2 (2H, m, CH₂); 3.6 (1H, m, CH); 4.8 (1H, d, OH); 7.5 (3H, m, CH); 8.2 (1H, m, CH); 8.6 (1H, m, CH); 8.9 (1H, d, CH).
- v) A solution of *E*-[4-(hydroxy)piperidin-1-ylsulphonyl]-2-(3-pyridyl)ethene in DMF (0.2g; 0.75mmol in 3ml) was added to 2,3-dichloropyridine (1.5mmol). A covering of argon gas was introduced to the tube before solid sodium hydride (0.1g incl. oil) was carefully added, in three portions the stirred reaction. Stirring was continued overnight. Water (5ml) was added (dropwise initially) and the resultant mixture extracted with EtOAc (5ml). The organic layer was separated and the aqueous layer washed again with EtOAc (3ml). The combined organics were evaporated, re-dissolved in DCM (5ml) and applied to a 10g Silica BondElut column and eluted with a gradient from DCM to 2.5% MeOH in DCM. Fractions containing pure product were evaporated. This material was dissolved in THF (1ml) and 50%




-58-





aqueous hydroxylamine (1ml) added and the mixture stirred vigorously at RT over night. After partition between water and ethyl acetate, the organic layer was evaporated to dryness to give (R/S)-2-((4-[(3-chloropyridin-2-yl)oxy]piperidin-1-yl)sulphonyl)-1-pyridin-3-ylethyl hydroxylamine.

5

EXAMPLES 23-29

The procedure described in Example 22 was followed except that the 2,3-dichloropyridine starting material used was replaced by the halo heterocycle described.


Example	Structure and name	Starting phenol	MH+
23	 <p>(R/S)-2-((4-[(3-cyanopyridin-2-yl)oxy]piperidin-1-yl)sulphonyl)-1-pyridin-3-ylethyl(hydroxy)formamide</p>	2-chloro-3-cyanopyridine	432
24	 <p>(R/S)-2-((4-[(8-chloroquinolin-4-yl)oxy]piperidin-1-yl)sulphonyl)-1-pyridin-3-ylethyl(hydroxy)formamide</p>	4,8-dichloroquinoline	491
25	 <p>(R/S)-hydroxy{1-pyridin-3-yl-2-[(4-[(3-trifluoromethylpyridin-2-yl)oxy]piperidin-1-yl)sulphonyl)]}</p>	2-chloro-3-trifluoromethylpyridine	474

	(trifluoromethyl)pyridin-2-yl]oxy} piperidin-1-yl)sulphonyl]ethyl} formamide		
26	 <p>(R/S)-2-[(4-{[3-chloro-5-trifluoromethyl]pyridin-2-yl]oxy}piperidin-1-yl)sulphonyl]-1-pyridin-3-ylethyl(hydroxy)formamide</p>	2,3-dichloro-5-trifluoromethyl pyridine	509
27	 <p>(R/S)-2-[(4-{[3-chloro-5-chloropyridin-2-yl]oxy}piperidin-1-yl)sulphonyl]-1-pyridin-3-ylethyl(hydroxy)formamide</p>	2,3,5-trichloro pyridine	475
28	 <p>(R/S)-hydroxy[2-({4-[(5-methylthieno[2,3-d]pyrimidin-4-yl]oxy}piperidin-1-yl)sulphonyl]-1-pyridin-3-ylethyl]formamide</p>	4-chloro-5-methylthieno[2,3-d]pyrimidine	478
29	 <p>(R/S)-hydroxy[2-({4-[(7-methylthieno[3,2-d]pyrimidin-4-yl]oxy}piperidin-1-yl)sulphonyl]-1-pyridin-3-ylethyl]formamide</p>	4-chloro-7-methylthieno[3,2-d]pyrimidine	478

	d]pyrimidin-4-yl)oxy]piperidin-1-yl]sulphonyl)-1-pyridin-3-ylethyl]formamide		
--	--	--	--

EXAMPLE 30

(R/S)-2-([4-(4-fluoro-2-thien-3-ylphenoxy)piperidin-1-yl]sulphonyl)methyl)-N-hydroxy-4-methylpentanamide



5 Trimethylaluminium (0.5ml of a 2M solution in toluene) was added to a suspension of hydroxylamine hydrochloride (65 mg) in toluene at 5 °C under inert atmosphere. The mixture was allowed to warm to RT over 90 minutes before adding a solution of (R/S)-methyl 2-([4-(4-fluoro-2-thien-3-ylphenoxy)piperidin-1-yl]sulphonyl)methyl)-4-methylpentanoate (80 mg)

10 in dry toluene (1ml). The mixture was stirred at ambient temperature for 1 hour before partitioning between 2N hydrochloric acid and ethylacetate. The organic phase was dried (Na₂SO₄) and dried under vacuum to yield the product as a yellow gum (48 mg). NMR (CDCl₃): 0.84-0.96 (6H, m), 1.1-1.91 (7H, m), 2.62-2.74 (2H, m), 2.93-3.06 (2H, m), 3.14-3.28 (3H, m), 4.4-4.48 (1H, m), 6.9-6.98 (2H, m), 7.13-7.20 (2H, m), 7.23-7.30 (1H, m), 7.35-

15 7.40 (2H, m), 7.51-7.56 (1H, m)

The starting (R/S)-methyl 2-([4-(4-fluoro-2-thien-3-ylphenoxy)piperidin-1-yl]sulphonyl)methyl)-4-methylpentanoate was prepared as follows:

i) DIAD (16 ml) was added dropwise to a solution of triphenylphosphine (21.5 g), 2-bromo-4-fluorophenol (15.6 g) and *tert*-butyl-4-hydroxy-1-piperidinecarboxylate (15 g) in tetrahydrofuran (200 ml) at 20 °C under an inert atmosphere. After stirring at ambient temperature for 4 hours the mixture was partitioned between water and EtOAc. The organic phase was washed with 2N sodium hydroxide solution and water, dried (MgSO₄) and evaporated under vacuum to yield a yellow oil. This was triturated with ether and a white

25 precipitate was isolated by filtration. The filtrates were purified by column chromatography using a gradient of isohexane to 20% EtOAc in isohexane as the eluant to yield *tert*-butyl 4-

-61-

(2-bromo-4-fluorophenoxy)piperidine-1-carboxylate as a clear oil (17.2 g). NMR (CDCl₃): 1.49 (9H, s), 1.75-1.95 (4H, m), 3.39-3.49 (2H, m), 3.62-3.74 (2H, m), 4.21-4.29 (1H, m), 6.85-7.01 (2H, m) and 7.26-7.34 (1H, m).

ii) TFA (20 ml) was added to a solution of *tert*-butyl 4-(2-bromo-4-fluorophenoxy)piperidine-1-carboxylate (19g) in DCM (200ml) at ambient temperature. After stirring at RT for 3 hours the mixture was evaporated under vacuum and partitioned between DCM and 2N sodium hydroxide solution. The organic phase was dried (MgSO₄) and evaporated under vacuum to yield 4-(2-bromo-4-fluorophenoxy)piperidine as a clear oil (12.77g). NMR (CDCl₃) 1.72-1.84 (2H, m), 1.94-2.05 (2H, m), 2.33 (1H, bs), 2.71-2.82 (2H, m), 3.15-3.26 (2H, m), 4.3-4.41 (1H, m), 6.84-7 (2H, m), 7.26-7.33 (1H, m).

iii) — Methanesulphonyl chloride (2ml) was added to a solution of 4-(2-bromo-4-fluorophenoxy)piperidine (6g) and triethylamine (3.8ml) in DCM (150ml) at RT and an exotherm was seen. After stirring at RT for a further 2 hours the mixture was washed with water, dried (MgSO₄), evaporated under vacuum and purified by column chromatography using 50% EtOAc / isohexane as the eluant to yield 4-(2-bromo-4-fluorophenoxy)-1-(methanesulphonyl)piperidine as a white solid (6.5g). NMR (CDCl₃): 1.92-2.1 (4H, m), 3.02 (3H, s), 3.27-3.39 (2H, m), 2.02-2.11 (2H, m), 4.51-4.6 (1H, m), 6.84-6.9 (1H, m), 6.95-7.03 (1H, m), 7.29-7.33 (1H, m); MS: 352.5/354.5.

iv) LHMDs (13.5 ml) was added over 10 minutes to a solution of 4-(2-bromo-4-fluorophenoxy)-1-(methanesulphonyl)piperidine (4.5 g) in dry THF (45 ml) at -20 °C under an inert atmosphere (solution A). At the same time LHMDs (13.5 ml) was added to a solution of DL- α -bromocaproic acid (2.64 g) in dry THF (35 ml) at -20 °C under inert atmosphere. After stirring at -20 °C for a further 10 minutes this was added to solution A and the mixture was allowed to warm to RT over 2 ½ hours. Aqueous ammonium chloride solution was added followed by 6N aqueous hydrogen chloride solution until the mixture was just acidic. The reaction mixture was partitioned between water and EtOAc. The organic phase was dried (Na₂SO₄), evaporated under vacuum and purified using a gradient of DCM to 3% MeOH in DCM to yield (R/S)-2-([4-(2-bromo-4-fluorophenoxy)piperidin-1-yl]sulphonyl)methyl-4-methylpentanoic acid as a clear oil. NMR (CDCl₃): 0.9-1.1 (6H, m), 1.4-1.51 (1H, m), 1.6-1.73 (2H, m), 1.9-2.0 (4H, m), 2.91-3.09 (2H, m), 3.31-3.55 (5H, m), 4.49-4.57 (1H, m), 6.85-6.91 (1H, m), 6.94-7.02 (1H, m), 7.28-7.32 (1H, m); MS (M-H⁺): 466/464


-62-

v) DMF (1 drop) was added to a mixture of (R/S)-2-([4-(2-bromo-4-fluorophenoxy)piperidin-1-yl]sulphonyl)methyl)-4-methylpentanoic acid (320 mg) and oxalyl chloride (10 ml) in DCM (10 ml). The mixture was stirred at RT for 1 hour before evaporating under vacuum to yield a white solid. This was dissolved in MeOH (20 ml, dry) and stirred at
 5 RT for 18 hours. The mixture was dried under vacuum and purified by column chromatography using a gradient of DCM to 10% MeOH in DCM as the eluant to yield (R/S)-methyl 2-([4-(2-bromo-4-fluorophenoxy)piperidin-1-yl]sulphonyl)methyl)-4-methylpentanoate as a clear gum (285 mg). NMR (CDCl₃): 1.9-1.98 (6H, m), 1.34-1.44 (1H, m), 1.52-1.66 (2H, m), 1.92-2.01 (4H, m), 2.87-3.07 (2H, m), 3.39-3.53 (5H, m), 3.74 (3H, s),
 10 4.49-4.55 (1H, m), 6.82-6.89 (1H, m), 6.94-7.01 (1H, m), 7.27-7.32 (1H, m).

vi) A mixture of (R/S)-methyl 2-([4-(2-bromo-4-fluorophenoxy)piperidin-1-yl]sulphonyl)methyl)-4-methylpentanoate (285 mg), 3-thienylboronic acid (230mg), water (1ml) and sodium hydrogen carbonate (150mg), in dimethoxyethane (10ml) was degassed with an argon purge before adding Pd(PPh₃)₄ (catalytic). The mixture was heated to 85 °C
 15 under argon for 18 hours before partitioning between 2N aqueous HCl and EtOAc. The organic phase was dried (MgSO₄), evaporated under vacuum and purified by column chromatography using a gradient of isohexane to 30% EtOAc in hexane as the eluant to yield (R/S)-methyl 2-([4-(4-fluoro-2-thien-3-ylphenoxy)piperidin-1-yl]sulphonyl)methyl)-4-methylpentanoate as a yellow gum (196 mg). NMR (CDCl₃): 0.9-1.01 (6H, m), 1.34-1.45
 20 (1H, m), 1.5-1.66 (2H, m), 1.82-1.95 (4H, m), 2.69-2.79 (1H, m), 2.93-3.15 (3H, m), 2.99-3.13 (3H, m), 3.7 (3H, s), 4.4-4.49 (1H, m), 6.9-7 (2H, m), 7.12-7.30 (1H, m), 7.33-7.42 (2H, m), 7.5-7.57 (1H, m); MS: 484.

EXAMPLE 31

25 (R/S)- 2-([4-(4-fluoro-2-pyridin-3-ylphenoxy)piperidin-1-yl]sulphonyl)methyl)-N-hydroxy-4-methylpentanamide



The title compound was made from methyl (R/S)-2-([4-(4-fluoro-2-pyridin-3-ylphenoxy)piperidin-1-yl]sulphonyl)methyl)-4-methylpentanoate (311 mg) (described below) by the same method as described in Example 30 to yield (R/S)-2-([4-(4-fluoro-2-pyridin-3-ylphenoxy)piperidin-1-yl]sulphonyl)methyl)-N-hydroxy-4-methylpentanamide as a gum (70 mg). NMR (CDCl₃): 0.94 (6H, d), 1.43-1.94 (7H, m), 2.55-2.63 (1H, m), 2.82-3.03 (3H, m), 3.22-3.42 (1H, m), 3.51-3.66 (2H, m), 4.54-4.6 (1H, m), 6.89-6.91 (1H, m), 7.02-7.12 (2H, m), 7.43-7.5 (1H, m), 7.79 (1H, d), 8.56 (1H, d), 8.94 (1H, s); MS: 480.


The starting (R/S)-2-([4-(4-fluoro-2-pyridin-3-ylphenoxy)piperidin-1-yl]sulphonyl)methyl)-4-methylpentanoate was prepared as follows:

i) (R/S)-2-([4-(4-fluoro-2-pyridin-3-ylphenoxy)piperidin-1-yl]sulphonyl)methyl)-4-methylpentanoate was made from (R/S)-methyl 2-([4-(2-bromo-4-fluorophenoxy)piperidin-1-yl]sulphonyl)methyl)-4-methylpentanoate (750 mg) (described within part v of Example 30) by the same method as for (R/S)-methyl 2-([4-(4-fluoro-2-thien-3-ylphenoxy)piperidin-1-yl]sulphonyl)methyl)-4-methylpentanoate except 3-thiophene boronic acid was replaced by 3-pyridine boronic acid to yield 480 mgs of product. NMR (CDCl₃): 0.89-0.96 (6H, m), 1.34-2.02 (1H, m), 1.48-1.63 (2H, m), 1.73-2.33 (4H, m), 2.67-2.75 (1H, m), 2.91-3.03 (3H, m), 3.15-3.28 (3H, m), 3.67 (3H, s), 4.35-4.22 (1H, m), 6.93-7.09 (3H, m), 7.33-7.40 (1H, m), 7.80-7.86 (1H, m), 8.59 (1H, dd), 8.78-8.79 (1H, m). MS: 479.

20

EXAMPLE 33

(R/S)-2-([4-(2-bromo-4-fluorophenoxy)piperidin-1-yl]sulphonyl)methyl)-N-hydroxy-4-methylpentanamide




25 Oxalyl chloride (5 ml) and DMF (one drop) were added to a solution of (R/S)-2-([4-(2-bromo-4-fluorophenoxy)piperidin-1-yl]sulphonyl)methyl)-4-methylpentanoic acid (140 mg) (described within Example 30) in DCM (3 ml). The mixture was stirred at RT for 1½ hours

before removing the solvent by evaporation under reduced pressure, redissolving in DCM (5 ml) and adding to a mixture of 50% hydroxylamine in water (0.5 ml) and THF (3 ml). After stirring at RT overnight the mixture was partitioned between ammonium chloride and EtOAc. The organic phase was dried, evaporated under reduced pressure and purified by column chromatography using a gradient of DCM to 3% MeOH in DCM as the eluant to yield (R/S)-2-([4-(2-bromo-4-fluorophenoxy)piperidin-1-yl]sulphonyl)methyl-N-hydroxy-4-methylpentanamide as a clear gum (28 mg). NMR (CDCl₃): 0.89-1.01 (6H, m), 1.23-2.07 (7H, m), 2.70-2.96 (2H, m), 3.34-3.51 (5H, m), 4.48-4.57 (1H, m), 6.83-7.03 (2H, m), 7.25-7.36 (2H, m); MS (M-H) 497/481.

10

EXAMPLE 34

(R/S)- 3-([4-(2-bromo-4-fluorophenoxy)piperidin-1-yl]sulphonyl)-2-cyclopentyl-N-hydroxypropanamide



15

The title compound was made from (R/S)-3-([4-(2-bromo-4-fluorophenoxy)piperidin-1-yl]sulphonyl)-2-cyclopentylpropanoic acid (described below) using the method described in Example 33 to yield (R/S)- 3-([4-(2-bromo-4-fluorophenoxy)piperidin-1-yl]sulphonyl)-2-cyclopentyl-N-hydroxypropanamide as a white foam (107 mg). NMR: 1.08-1.99 (13H, m), 2.31 (1H, t), 2.98 (1H, d), 3.09-3.52 (5H, m), 4.55-4.64 (1H, m), 7.14-7.25 (2H, m), 7.50-7.57 (1H, m) and 10.525 (1H, bs); MS (M-H): 493.

20

The starting (R/S)-3-([4-(2-bromo-4-fluorophenoxy)piperidin-1-yl]sulphonyl)-2-cyclopentylpropanoate was prepared as described below:

25 i) Sodium metal (2.88g) was added in small portions to absolute ethanol (220ml) under argon with stirring at RT. On achievement of complete solution, a mixture of diethyl malonate (20g) and cyclopentyl bromide (18.64g) was added and the mixture stirred under reflux for 2 hours, allowed to cool and excess solvent removed in vacuo. The residue was partitioned between water (150ml) and Et₂O (3x200ml) and combined organics were dried (sodium

-65-

sulphate), concentrated in vacuo and purified on a 100g silica bond elute using a 5-35% EtOAc/isohexane gradient over 50 minutes as eluent to give diethyl cyclopentylmalonate as a colourless oil (18.34g); NMR: δ 1.1 (m, 9H), 1.5 (m, 4H), 1.7 (m, 2H), 2.3 (m, 1H), 4.1 (q, 4H).

5 ii) 3M aqueous sodium hydroxide (200ml) was added to a stirred solution of diethyl cyclopentylmalonate (18.33g) in THF (300ml) and MeOH (300ml). Stirring was continued overnight and organic solvents removed in vacuo. The resulting aqueous solution was saturated with salt, acidified with concentrated hydrochloric acid and partitioned three times with ethyl acetate. The combined organic extracts were dried (MgSO_4), concentrated in vacuo
10 and azeotroped once with toluene to give cyclopentylmalonic acid as an off-white solid (12.7g); NMR: δ 1.2 (m, 2H), 1.5 (m, 4H), 1.7 (m, 2H), 2.25 (m, 1H), 3.0 (d, 1H), 12.5 (s, 2H); MS: 171.18 (ES⁻).

iii) Morpholine (7.08ml) was added to a stirred solution of cyclopentylmalonic acid (12.69g) in water (55ml) and acetic acid (9ml) at RT. After 20 minutes 37% aqueous
15 formaldehyde (3.33g) was added and stirring was continued overnight. The reaction was then heated to 80°C and maintained for 2 hours, allowed to cool to RT and made basic with solid sodium hydrogen carbonate. This solution was washed with DCM (100ml) and then acidified using 2M hydrochloric acid followed by concentrated hydrochloric acid and partitioned with DCM (3x150ml). Combined organic extracts were washed with water (100ml) and brine
20 (100ml), dried (MgSO_4) and concentrated in vacuo to give 2-cyclopentylprop-2-enoic acid as a white solid (2.8g); NMR: δ 1.3(m, 2H), 1.6(m, 4H), 1.8(m, 2H), 2.85(m, 1H), 5.5(s, 1H), 6.0(s, 1H) and 12.3(s, 1H); MS 139.11 (ES⁻).

iv) Hydrogen bromide (30 wt.% solution in acetic acid, 22ml) was added to 2-cyclopentylpropenoic acid (2.8g). The mixture was stirred at RT overnight and then poured
25 cautiously into water (130ml) and partitioned with EtOAc (3x75ml). The combined organic extracts were treated with water (50ml) and brine (50ml), dried (MgSO_4), concentrated in vacuo and azeotroped twice with toluene. The crude product was purified on a 50g silica bond elute using a 25-50% EtOAc/isohexane gradient over 45 minutes as eluent to give (R/S)-3-bromo-2-cyclopentylpropionic acid as a pale yellow solid (2.51g); NMR: δ 1.2(m, 2H), 1.6(m,
30 6H), 1.9(m, 1H), 2.5(m, 1H+DMSO-d₆), 3.6(m, 2H); MS: 223.23(ES⁺), 221.15 (ES⁻).

v) (R/S)-3-Bromo-2-cyclopentylpropionic acid (2.5g) was mixed with DCM (35ml), isobutylene (18ml) and concentrated sulphuric acid (2 drops) and the reaction was carried out

at 25°C for 48 hours at a pressure of 1 bar (high pressure facility). The solution was treated with saturated aqueous sodium hydrogen carbonate (50ml), dried and concentrated in vacuo to give (R/S)-*tert*-butyl-3-bromo-2-cyclopentylpropionate as a light green oil (1.2g); NMR: δ 1.3 (m, 3H), 1.4 (s, 9H), 1.6(m, 5H), 1.9 (m, 1H), 2.5(m, 1H), 3.6(m, 2H); MS 278 (ES+).



- 5 vi) Potassium thioacetate (1.23g) was added to a stirred solution of (R/S)-*tert*-butyl-3-bromo-2-cyclopentylpropionate (1.19g) in DMF (25ml) under argon at RT. The solution was heated to 100°C and maintained for 3 hours, then allowed to cool, poured into water (100ml) and partitioned with EtOAc (3x150ml). Combined organic extracts were treated with saturated aqueous sodium hydrogen carbonate (50ml), water (50ml) and brine (50ml), dried
10 (sodium sulphate), concentrated in vacuo and purified on a 20g silica bond elute using a 0-10% ethyl acetate/isohexane gradient over 45 minutes as eluent to give (R/S)-*tert*-butyl-3-acetylthio-2-cyclopentylpropionate as a light brown oil (870mg); NMR: δ 1.2(m, 3H), 1.4(s, 9H), 1.5(m, 4H), 1.8(m, 1H), 1.9(m, 1H), 2.2(m, 1H), 2.3(s, 3H) and 3.0(m, 2H); MS: 273(ES+), 271(ES-).
- 15 vii) (R/S)-*Tert*-butyl-3-acetylthio-2-cyclopentylpropionate (860mg) was suspended in 5% acetic acid in water (50ml) and stirred at room temperature. Chlorine gas was bubbled through the suspension for 30 minutes. The chlorine source was then removed and the reaction stirred for a further 30 minutes. The mixture was partitioned with DCM (3x100ml) and combined organic extracts treated with water (50ml) and brine (50ml), dried (magnesium sulphate),
20 concentrated in vacuo and azeotroped once with toluene to give (R/S)-*tert*-butyl-3-chlorosulphonyl-2-cyclopentylpropionate as a pale yellow oil (930mg); NMR (CDCl₃): δ 1.4(m, 2H), 1.5(s, 9H), 1.7(m, 6H), 2.1(m, 1H), 2.9(m, 1H) and 3.9(m, 2H); MS 296.61(ES+).
- viii) (R/S)-*Tert*-butyl-3-chlorosulphonyl-2-cyclopentylpropionate (486 mg) was added to a mixture of 4-(2-bromo-4-fluorophenoxy)piperidine (430 mg) (described in example 30) and
25 triethylamine (0.22 ml) in DCM at ambient temperature. After stirring at ambient temperature for 18 hours the mixture was washed with water, dried (phase separating cartridge), evaporated under vacuum and purified by column chromatography using a gradient of isohexane to 20% EtOAc/ isohexane. (R/S)-*Tert*-butyl 3-{[4-(2-bromo-4-fluorophenoxy)piperidin-1-yl]sulphonyl}-2-cyclopentylpropanoate was obtained as a white
30 solid (420 mg). NMR (CDCl₃): 1.17-1.85 (17H, m), 1.94-2.05 (5H, m), 2.6-2.7 (1H, m), 2.92-3.01 (1H, m), 3.4-3.58 (5H, m), 4.49-4.56 (1H, m), 6.83-6.91 (1H, m), 6.95-7.02 (1H, m), 7.25-7.34 (1H, m).

-67-



ix) TFA (20 ml) was added to a solution of (R/S)-*tert*-butyl 3-{{4-(2-bromo-4-fluorophenoxy)piperidin-1-yl}sulphonyl}-2-cyclopentylpropanoate (210 mg) in DCM (20 ml). The mixture was stirred at ambient temperature for 3 ½ hours before removing the solvent by evaporation under reduced vacuum to yield (R/S)-3-{{4-(2-bromo-4-fluorophenoxy)piperidin-1-yl}sulphonyl}-2-cyclopentylpropanoic acid as a gum (175 mg). NMR (CDCl₃): 0.78-2.10 (13H, m), 2.75-2.82 (1H, m), 3.00-3.09 (1H, m), 3.31-3.60 (5H, m), 3.7-3.95 (1H, bs), 4.49-4.56 (1H, m), 6.83-6.90 (1H, m), 6.91-7.01 (1H, m), 7.27-7.33 (1H, m).

EXAMPLE 35-38

10 The method shown in Example 2 was followed except that 2-chloro-4-trifluoromethylphenol was replaced by the appropriate aryl alcohol derivative to give the products shown below.


Example	Structure and name	Starting phenol	MH ⁺
35	 <p>(R/S)- 1-(((4-[1-naphthyloxy]piperidin-1-yl)sulphonyl)methyl)-4-pyrimidin-2-ylbutyl(hydroxy)formamide</p>	1-hydroxy naphthalene	499
36	 <p>(R/S)- 1-(((4-[2-chloro-4-fluorophenoxy]piperidin-1-yl)sulphonyl)methyl)-4-pyrimidin-2-ylbutyl(hydroxy)formamide</p>	2-chloro-4-fluorophenol	501

-68-

37	 <p>(R/S)- 1-[(4-[2-bromo-4,6-difluorophenoxy]piperidin-1-yl)sulphonyl)methyl]-4-pyrimidin-2-ylbutyl(hydroxy)formamide</p>	2-bromo-4,6-difluorophenol	563
38	 <p>(R/S)- 1-[(4-[2,4-dichlorophenoxy]piperidin-1-yl)sulphonyl)methyl]-4-pyrimidin-2-ylbutyl(hydroxy)formamide</p>	2,4-dichlorophenol	517

EXAMPLE 39

(R/S)- 1-[(4-[2-cyanophenoxy]piperidin-1-yl)sulphonyl)methyl]-4-pyrimidin-2-ylbutyl(hydroxy)formamide



5

The method described in Example 2 was followed except that 1-*tert*-butyl-4-(2-chloro-4-trifluoromethylphenoxy)piperidine carboxylate was replaced by 1-*tert*-butyl-4-(2-cyanophenoxy)piperidine carboxylate to give (R/S)-1-[(4-[2-cyanophenoxy]piperidin-1-yl)sulphonyl)methyl]-4-pyrimidin-2-ylbutyl(hydroxy)formamide as a cream solid (0.61g);

10 NMR (CDCl₃): 1.4-1.9 (8H, m), 2.7-2.9 (3H, m), 3.0-3.4 (5H, m), 4.0 (1H, m)*, 4.5 (1H, m), 4.7 (1H, m)*, 6.8 (2H, m), 7.0 (1H, m), 7.3 (2H, m), 7.8 (1H, s)*, 8.2 (1H, s)* and 8.4 (2H, m). MS: 474.

*=rotameric signals.

-69-

The starting 1-*tert*-butyl-4-(2-cyanophenyloxy)piperidine carboxylate was prepared as follows:

- i) To a stirred solution of sodium hydride (1.32g, 33mmol) in DMF (100ml) under argon was added 1-*tert*-butyl-4-hydroxypiperidine carboxylate (5.5g, 27.5mmol) followed by 2-fluorobenzenenitrile (3ml, 27.5mmol). After 15 hours the mixture was concentrated and ethyl acetate was added. The mixture was washed (water and brine), dried (MgSO₄) and concentrated to give 1-*tert*-butyl-4-(2-cyanophenyloxy)piperidine carboxylate as a crude material (8g, 26.5mmol); MS: 203 (MH⁺-Boc).

10

15

20


25

30

CLAIMS:

What we claim is:-

1. A compound of formula (1):



formula (1)

wherein:

Z is selected from $-\text{CONR}^{15}\text{OH}$ and $-\text{N}(\text{OH})\text{CHO}$;

R^{15} is hydrogen or C_{1-3} alkyl;

R^1 is hydrogen or a group selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, C_{5-7} cycloalkenyl, aryl and heteroaryl where the group is optionally substituted by one or more substituents independently selected from halo, nitro, cyano, trifluoromethyl, trifluoromethoxy, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{3-6} cycloalkyl (optionally substituted by one or more R^{17}), aryl (optionally substituted by one or more R^{17}), heteroaryl (optionally substituted by one or more R^{17}), heterocyclyl, C_{1-4} alkoxycarbonyl, $-\text{OR}^5$, $-\text{SR}^2$, $-\text{SOR}^2$, $-\text{SO}_2\text{R}^2$, $-\text{COR}^2$, $-\text{CO}_2\text{R}^5$, $-\text{CONR}^5\text{R}^6$, $-\text{NR}^{16}\text{COR}^5$, $-\text{SO}_2\text{NR}^5\text{R}^6$ and $-\text{NR}^{16}\text{SO}_2\text{R}^2$;

R^{16} is hydrogen or C_{1-3} alkyl;

R^{17} is selected from halo, C_{1-6} alkyl, C_{3-6} cycloalkyl and C_{1-6} alkoxy;

R^2 is group selected from C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{5-7} cycloalkenyl, heterocycloalkyl, aryl, heteroaryl, aryl C_{1-4} alkyl and heteroaryl C_{1-4} alkyl where the group is optionally substituted by one or more halo;

R^5 is hydrogen or a group selected from C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{5-7} cycloalkenyl, heterocycloalkyl, aryl, heteroaryl, aryl C_{1-4} alkyl and heteroaryl C_{1-4} alkyl where the group is optionally substituted by one or more halo;

R^6 is hydrogen, C_{1-6} alkyl or C_{3-6} cycloalkyl;

or R^5 and R^6 together with the nitrogen to which they are attached form a heterocyclic 4- to 7-membered ring;

R^8 is hydrogen or a group selected from C_{1-6} alkyl, C_{3-7} cycloalkyl and C_{5-7} cycloalkenyl where the group is optionally substituted by one or more substituents independently selected from halo, nitro, cyano, trifluoromethyl, trifluoromethoxy and C_{1-4} alkyl;

-71-

R^3 and R^4 are both hydrogen;

n is 0 or 1;

m is 0 or 1;

D is hydrogen, C_{1-4} alkyl, C_{3-6} cycloalkyl or fluoro;

5 X is O, S, SO or SO_2 ;

B is monocyclic aryl or heteroaryl where each is substituted in an ortho position by, and is optionally further substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo, C_{1-4} alkyl (optionally substituted by R^{13}), C_{2-4} alkenyl (optionally substituted by R^{13}), C_{2-4} alkynyl (optionally substituted by R^{13}), C_{3-6} cycloalkyl (optionally substituted by R^{13}), C_{3-6} cycloalkenyl (optionally substituted by R^{13}), phenyl (optionally substituted by halo or C_{1-4} alkyl), heteroaryl (optionally substituted by halo or C_{1-4} alkyl), heterocyclyl (optionally substituted by halo or C_{1-4} alkyl), C_{1-4} alkylthio, C_{3-6} cycloalkylthio, $-SOR^{13}$, $-SO_2R^{13}$, $-SO_2NHR^{13}$, $-SO_2NR^{13}R^{14}$, $-NHSO_2R^{13}$, $-NR^{13}SO_2R^{14}$, $-NHCONHR^{13}$, $-NHCONHR^{13}R^{14}$, $-OR^{13}$, cyano, $-CONR^{13}R^{14}$, $-NHCOR^{13}$, $-CO^2R^{13}$ and $-CH_2CO_2R^{13}$;

15 or B is bicyclic aryl or heteroaryl where each is optionally substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo, C_{1-4} alkyl (optionally substituted by R^{13}), C_{2-4} alkenyl (optionally substituted by R^{13}), C_{2-4} alkynyl (optionally substituted by R^{13}), C_{3-6} cycloalkyl (optionally substituted by R^{13}), C_{3-6} cycloalkenyl (optionally substituted by R^{13}), C_{1-4} alkylthio, C_{3-6} cycloalkylthio, $-SOR^{13}$, $-SO_2R^{13}$, $-SO_2NHR^{13}$, $-SO_2NR^{13}R^{14}$, $-NHSO_2R^{13}$, $-NR^{13}SO_2R^{14}$, $-NHCONHR^{13}$, $-NHCONHR^{13}R^{14}$, $-OR^{13}$, cyano, $-CONR^{13}R^{14}$ and $-NHCOR^{13}$;

R^{13} and R^{14} are independently hydrogen, C_{1-6} alkyl or C_{3-6} cycloalkyl;

or R^{13} and R^{14} together with the nitrogen to which they are attached form a heterocyclic 4 to

25 7-membered ring.

or a pharmaceutically acceptable salt thereof.


2. A compound according to claim 1 wherein B is phenyl or pyridyl where each is substituted in an ortho position by, and is optionally further substituted by one or more groups independently selected from halo, trifluoromethyl, cyano, C_{1-4} alkoxy, C_{1-4} alkyl, nitro, aryl, heteroaryl, heterocyclyl, N -(C_{1-4} alkyl)carbamoyl and N,N -(C_{1-4} alkyl) $_2$ carbamoyl; or B is naphthyl, quinolinyl, thieno[2,3-*d*]pyrimidinyl or thieno[3,2-*d*]pyrimidinyl each being

-72-

optionally substituted by one or more groups independently selected from halo, trifluoromethyl, cyano, C₁₋₄alkoxy, C₁₋₄alkyl, aryl, heteroaryl, heterocyclyl and nitro.


3. A compound according to claim 1 or 2 wherein R¹ is a group selected from C₁₋₆alkyl,
5 C₃₋₆cycloalkyl, aryl, heteroaryl and C₁₋₆alkyl substituted by aryl or heteroaryl wherein any R¹
group is optionally substituted by one or more substituents independently selected from halo,
C₁₋₄alkoxy, C₁₋₄alkyl and C₃₋₆cycloalkyl.
4. A compound according to any one of claims 1 to 3 wherein X is O.
- 10 5. A compound according to any one of claims 1 to 4 for use as a medicament.
6. The use of a compound according to any one of claims 1 to 4 in the manufacture of a
medicament in the treatment of a disease condition mediated by one or more
15 metalloproteinase enzymes.
7. The use of a compound according to any one of claims 1 to 4 in the manufacture of a
medicament in the treatment of a disease condition mediated TNF α .
- 20 8. A pharmaceutical composition comprising a compound according to any one of claims
1 to 4; and a pharmaceutically-acceptable diluent or carrier.
9. A method of treating autoimmune disease, allergic/atopic diseases, transplant
rejection, graft versus host disease, cardiovascular disease, reperfusion injury and malignancy
25 in a warm-blooded animal, such as man, in need of such treatment which comprises
administering to said animal an effective amount of a compound according to claim 1.
10. A process for preparing a compound of formula (1) according to claim 1 comprising,
when Z is -N(OH)CHO, the step of:
30 a) converting a hydroxylamine of formula (2) into a compound of formula (1);

-73-



or when Z is $-\text{CONR}^{15}\text{OH}$, the step of:

b) converting an acid of formula (14) into a compound of formula (1);



5 and thereafter if necessary:

- i) converting a compound of formula (1) into another compound of formula (1);
- ii) removing any protecting groups;
- iii) forming a pharmaceutically acceptable salt or *in vivo* hydrolysable ester.

INTERNATIONAL SEARCH REPORT

Internat Application No.
PCT/GB 03/02982

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/445 A61P37/00 C07D413/12 C07D401/12 C07D211/96
C07D401/14 C07D495/04 C07D409/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 12478 A (ZENECA PHARMA SA ;TUCKER HOWARD (GB); WATERSON DAVID (GB); ZENECA) 9 March 2000 (2000-03-09) cited in the application claim 1	1-10
X	WO 01 87870 A (DARWIN DISCOVERY LTD) 22 November 2001 (2001-11-22) cited in the application claim 1	1-10
X	WO 99 24399 A (DARWIN DISCOVERY LTD) 20 May 1999 (1999-05-20) claim 1	1-10
	-/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

8 October 2003

Date of mailing of the international search report

15/10/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 apo nl,
Fax (+31-70) 340-3016

Authorized officer

Johnson, C

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB 03/02982

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 9 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/GB 03/02982

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 12477 A (BRITISH BIOTECH PHARM ; MARTIN FIONNA MITCHELL (GB)) 9 March 2000 (2000-03-09) cited in the application claim 6	1-10

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1(part), 2, 3-10 (part)

Compounds of formula (1) wherein B is an ortho-substituted monocyclic aryl or heteroaryl group.

2. Claims: 1, 3-10 (all part)

Compounds of formula (1) wherein B is a bicyclic aryl or heteroaryl group.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat Application No.

PCT/GB 03/02982

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0012478	A	09-03-2000	AU 764367 B2	14-08-2003
			AU 5524799 A	21-03-2000
			BG 105369 A	31-12-2001
			BR 9913255 A	22-05-2001
			CA 2339761 A1	09-03-2000
			CN 1324347 T	28-11-2001
			EE 200100106 A	17-06-2002
			EP 1109787 A1	27-06-2001
			WO 0012478 A1	09-03-2000
			HU 0103344 A2	28-02-2002
			JP 2002523493 T	30-07-2002
			NO 20011023 A	25-04-2001
			NZ 509730 A	30-05-2003
			PL 346344 A1	11-02-2002
			SK 2702001 A3	06-08-2001
			TR 200100605 T2	21-08-2001
			ZA 200101231 A	13-05-2002
WO 0187870	A	22-11-2001	AU 5854001 A	26-11-2001
			CA 2409035 A1	22-11-2001
			EP 1282614 A1	12-02-2003
			WO 0187870 A1	22-11-2001
			US 2002037900 A1	28-03-2002
WO 9924399	A	20-05-1999	AT 231837 T	15-02-2003
			AU 748843 B2	13-06-2002
			AU 1046999 A	31-05-1999
			BR 9814147 A	03-10-2000
			CA 2308359 A1	20-05-1999
			CN 1283183 T	07-02-2001
			DE 69811111 D1	06-03-2003
			DE 69811111 T2	24-07-2003
			DK 1030836 T3	26-05-2003
			EP 1030836 A1	30-08-2000
			ES 2190115 T3	16-07-2003
			WO 9924399 A1	20-05-1999
			HU 0100152 A2	28-02-2002
			JP 2001522832 T	20-11-2001
			NO 20002440 A	11-05-2000
			NZ 504387 A	25-10-2002
			PL 340551 A1	12-02-2001
			US 6187924 B1	13-02-2001
			ZA 9810360 A	12-11-1999
WO 0012477	A	09-03-2000	AU 5634999 A	21-03-2000
			EP 1107953 A1	20-06-2001
			WO 0012477 A1	09-03-2000
			JP 2002523492 T	30-07-2002
			US 2003050310 A1	13-03-2003
			US 6479502 B1	12-11-2002

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)